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Abstract
Background: Resistant bipolar disorder is a major mental health problem related to significant disability and overall cost. 
The aim of the current study was to perform a systematic review of the literature concerning (1) the definition of treatment 
resistance in bipolar disorder, (2) its clinical and (3) neurobiological correlates, and (4) the evidence-based treatment options 
for treatment-resistant bipolar disorder and for eventually developing guidelines for the treatment of this condition
Materials and Methods: The PRISMA method was used to identify all published papers relevant to the definition of treatment 
resistance in bipolar disorder and the associated evidence-based treatment options. The MEDLINE was searched to April 22, 2018.
Results: Criteria were developed for the identification of resistance in bipolar disorder concerning all phases. The search of the 
literature identified all published studies concerning treatment options. The data were classified according to strength, and 
separate guidelines regarding resistant acute mania, acute bipolar depression, and the maintenance phase were developed.
Discussion: The definition of resistance in bipolar disorder is by itself difficult due to the complexity of the clinical picture, 
course, and treatment options. The current guidelines are the first, to our knowledge, developed specifically for the treatment 
of resistant bipolar disorder patients, and they also include an operationalized definition of treatment resistance. They were 
based on a thorough and deep search of the literature and utilize as much as possible an evidence-based approach.
Keywords:  treatment resistant, refractoriness, anticonvulsants, antidepressants, antipsychotics, bipolar disorder, evidence-
based guidelines, lithium, mania, mood stabilizers, treatment
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Introduction
Bipolar disorder (BD) has been described since the times of 
Hippocrates and Areteus, but recently the subtypes BD-I and 
BD-II were proposed with a combined prevalence rate of up to 
2.4% (Merikangas et al., 2011). The treatment of BD is probably 
the most challenging of all mental disorders with the unique 
characteristic that each phase needs a different treatment ap-
proach (Vieta and Goikolea, 2005).
Such complex mental disorders are those that are ex-
pected to benefit more by the development of treatment guide-
lines, which during the last few decades are becoming an ever 
more important part of medical reality. This is especially since 
the translation of research findings to everyday clinical prac-
tice is becoming increasingly difficult with the accumulation 
of complex and often conflicting research findings, which are 
thereafter also included in meta-analysis. Guidelines aim to 
assist clinicians but also policymakers to arrive at decisions 
concerning the treatment and care of patients. They set the 
standard of care and training for health professionals, and they 
identify priority areas for further research since they are based 
primarily on the available evidence, but also, in areas where evi-
dence is not available, on expert opinion.
The literature suggests that depression rather than 
mania is the most challenging phase (Manning, 2005). If 
subsyndromal, the presence of residual symptoms impose a 
greater risk of relapse (Keller et  al., 1992), greater disability, 
and poorer overall outcome (Tohen et al., 1990a, 1990b, 2006). 
Therefore, full remission and recovery should be the ultimate 
treatment goal. A significant proportion of patients, however, 
do not fully respond to treatment, and their long-term course 
is characterized by frequent relapses and residual symptoms, 
causing significant disability and functional impairment (Esan 
et al., 2017).
To fulfil this need for expert translation of research find-
ings into clinical practice and for the benefit of patients, the 
International College of Neuropsychopharmacology (CINP) 
launched an effort to critically appraise the literature and 
provide guidance to clinicians in the form of a treatment algo-
rithm and guidelines as precise as the data allow. It is hoped 
that they will help the clinician to follow the state-of-the-art 
evidence, thus enabling their clinical practice to be based 
on informed decision-making process. They have been com-
missioned by the CINP, and the working group consisted of 
experts with extensive research and clinical experience in 
the field of BD. There was no funding from any source for 
the development of the guidelines and the activities of the 
working group.
All the members of the working group were psychiat-
rists who are in active clinical practice and were selected ac-
cording to their expertise with the aim to cover a multitude 
of different cultures. All of them were involved in research 
and other academic activities, and therefore it is possible 
that through such activities some contributors have received 
income related to medicines discussed in this guideline. All 
conflicts of interest are mentioned at the end of this paper, 
which is the introductory paper to the CINP BD guidelines. It 
should also be noted that some drugs recommended in the 
guideline may not be available in all countries, and labeling 
and dosing might vary.
This project has already developed treatment algorithms 
and guidelines for BD (Fountoulakis et al., 2017a, 2017b, 2017c, 
2017d), and the next step would be to search for data in the area 
of BD resistant to treatment.
Aim of the Current Study 
The aim of the current study was to perform a PRISMA sys-
tematic review of the literature concerning (1) the definition of 
treatment resistance in BD, (2) its clinical and (3) neurobiological 
correlates, and (4) the evidence-based treatment options for 
treatment-resistant BD.
Materials and Methods
The PRISMA method (Hopewell et al., 2008; Liberati et al., 2009; 
Moher et al., 2009) was followed in the search of the literature. 
We searched MEDLINE to April 22, 2018 with the combination 
of keywords “refractory” or “refractoriness” or “resistant” with 
“mania,” “manic,” “bipolar,” “manic-depressive,” or “manic-
depression.” The PRISMA flowchart is shown in Figure 1.
The following inclusion criteria were utilized:
 1. Papers in English language
 2. Papers reporting specifically on BD, not on affective 
disorders in general. If the paper concerned affective 
disorders in general then there should be a specific 
elaboration on BD.
 3. Concerning the definition of treatment resistance in BD: 
any paper that included a description or any kind of defin-
ition.
 4. Papers considering resistant bipolar depression on the basis 
of failure of antidepressant treatment were not included. 
An exception was made for those specific antidepressants 
with a proven efficacy in the treatment of BD according to 
the CINP Bipolar Disorder Treatment Guidelines.
 5. For clinical and neurobiological correlates we considered 
only papers with original data.
 6. Concerning treatment options, all papers with original 
data, systematic reviews, and meta-analyses as well as 
post-hoc analyses were included.
 7. Case reports and case series (including retrospective chart 
reviews) were not included (either referenced as such or ac-
cording to the author’s judgement).
Relevant review papers were scanned to locate additional 
studies (Poon et  al., 2012; Hui Poon et  al., 2015; Fountoulakis 
et al., 2017a; Grunze et al., 2018). The data concerning the treat-
ment of resistant BD were ranked according to the method pre-
viously developed by the authors (Fountoulakis et al., 2017d) and 
shown in Table 1.
Results
Definitions of Treatment Resistance in BD (n = 37)
There are several approaches to define “response,” “remission,” 
“recovery,” “relapse,” and “recurrence” in mental disorders. 
Although these definitions have been used in observational 
studies (Tohen et  al., 1990a, 1990b, 2003a, 2003b), a common 
starting point is that these definitions apply to patients who re-
ceived treatment with an adequate dosage of an effective treat-
ment modality for a sufficient duration of time. Patients unable 
to tolerate such an adequate therapeutic trial for any reason 
as well as noncompliant patients are usually considered as 
“pseudorefractory” (Table 2).
Some authors suggest that the basis is an inadequate re-
sponse to a therapeutic trial of lithium or an inability to tol-
erate lithium’s side effects (Barton and Gitlin, 1987; Aronson 
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et al., 1989; Kramlinger and Post, 1989; Bauer, 1990; Pope, 1991; 
Schaff et  al., 1993; McElroy et  al., 1998; Altshuler et  al., 1999; 
Calabrese et al., 1999; Green et al., 2000). Others consider a dif-
ferent definition on the basis of nonresponse to carbamaze-
pine (Kramlinger and Post, 1989; Bauer, 1990; Schaff et al., 1993) 
or valproate (Calabrese et  al., 1999), and their definition of 
failure also included intolerance. A more restrictive definition 
of treatment resistance demands failure to respond to at least 
2 agents (McElroy et  al., 1991; Kimmel et  al., 1994; Calabrese 
et  al., 1996), while other authors defined wider degrees of 
treatment nonresponse (tertiary resistance) (Vieta et al., 1998; 
Ciapparelli et al., 2000; Green et al., 2000; Suppes et al., 2003; 
Sajatovic et al., 2006).
The first comprehensive attempt defined treatment-
resistant mania as mania without remission despite adequate 
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anticonvulsant, etc.) for at least 6 weeks on each agent in the ab-
sence of antidepressants or other mood-elevating agents (Sachs, 
1996). For resistant bipolar depression, an extrapolation of the 
definition for unipolar to bipolar depression would be appro-
priate, which means no remission despite 2 adequate trials of 
standard antidepressant agents (6 weeks each), with or without 
augmentation strategies (Sachs, 1996). However, this definition 
is currently not supported by the data in a fundamental way 
since antidepressants are not considered to be efficacious in 
the treatment of bipolar depression, although they are among 
the most commonly used agents (Baek et  al., 2014; Bjorklund 
et al., 2016; Kessing et al., 2016). Treatment-resistant mood cyc-
ling (resistance in the long term) was defined as continued cyc-
ling despite maximal tolerated lithium in combination with 
valproate or carbamazepine for a period of 3 times the average 
cycle length, or 6 months, whichever is longer, in the absence of 
antidepressants or other cycle-promoting agents (Sachs, 1996). 
This definition is not in accord with the data concerning the ef-
ficacious treatment of these conditions (Sachs, 1996).
The only attempt to grade treatment resistance of a stratified 
response/refractoriness graduation suggested the clustering of 
resistant cases into 3 groups: (1) primary resistance, that is, inad-
equate response to a therapeutic trial of lithium (>0.7 mmol/L), 
valproate, or carbamazepine; (2) secondary resistance, that is, 
inadequate response to sequential therapeutic trials of 2 mood 
stabilizers or an antipsychotic and a mood stabilizer; and (3) 
tertiary resistance, that is, inadequate response to sequential 
therapeutic trials of 3 agents: any antipsychotics, 2 mood stabil-
izers and an antipsychotic, 2 antipsychotics and a mood stabil-
izer, or 3 mood stabilizers (Keck and McElroy, 2001).
Another definition was based on the assumption that 
lithium at serum levels of 0.8 mmol/L or greater for at least 6 
weeks should be the first line of treatment for bipolar depres-
sion if a patient is not already on a mood stabilizer and if lithium 
fails, the addition of lamotrigine, carbamazepine, valproate, 
antidepressants (not tricyclic antidepressants), or an atypical 
antipsychotic such as olanzapine might be a reasonable second-
line options (Yatham et al., 2003a; Tohen et al., 2004; Taylor et al., 
2014). This is in partial agreement with the data currently avail-
able. In the STEP-BD study, treatment-resistant depression was 
defined as no response to treatment after 12 weeks of treatment 
or a well-documented failure to respond to at least 2 trials of 
antidepressants or an antidepressant and a mood stabilizer 
(Nierenberg et al., 2006).
A more sophisticated 4-level system for the staging of resist-
ance from resistance to a single agent to resistant to 3 agents 
plus neurostimulation has been proposed, but its clinical rele-
vance is unclear since it puts the emphasis on the number of 
Table 2. Issues to be addressed in order to label a patient as 
“resistant”
1. Correct diagnosis
2. Disorder not secondary to an organic disorder
3.  Poor response to treatment not due to somatic or mental 
comorbidity
4.  Poor response to treatment not due to a somatic condition that 
might not constitute a disorder by itself (e.g., genetic factors, 
smoking, alcohol use, gender, race, etc.)
5. Failure of therapy not due to nontolerability
6.  Patient complies with recommended treatment and poor 
response not a consequence of lack of adherence 
Table 1. Summary of the method for grading data and recommendation on the basis of both efficacy and safety/tolerability
Grading on basis of efficacy
Level 1 Good research-based evidence, supported by at least 2 placebo controlled studies of sufficient magnitude and good 
quality. In case of the presence of negative RCTs, positive RCTs should outnumber negative ones
Level 2 Fair research-based evidence, from 1 randomized, double-blind placebo controlled trial  
Also in case 1 or more trials exist, however, they fail to fulfil all the criteria above (e.g., very small sample size or no 
placebo control) as well as in case of positive meta-analysis alone
Level 3 Some evidence from comparative studies without placebo arm or from post-hoc analyses
Level 4 Inconclusive data or poor-quality RCTs
Level 5 Negative data
Grading on the basis of safety and tolerability
Level 1 Very good tolerability, few side effects that are not enduring, do not cause significant distress, and are not life-
threatening and do not compromise the overall somatic health of patient
Level 2 Moderate tolerability, many side effects that could be enduring, and cause significant distress but are not life-
threatening, although they could compromise the overall somatic health of the patient  
Agents with very good overall tolerability but with rare life-threatening adverse events, could be classified here only 
if the lethality risk can be essentially considered to be negligible with application of procedures and protocols (e.g., 
laboratory testing, titration schedules, etc.)
Level 3 Poor tolerability, many side effects that are enduring, cause significant distress, compromise the overall somatic 
health of patient, or are life-threatening  
Agents with moderate overall tolerability and rare, life-threatening adverse events should be classified here even in 
case the lethality risk can be essentially considered to be negligible with the application of procedures and protocols 
(e.g., laboratory testing, titration schedules, etc.)
Recommendations for treatment (combination of efficacy and safety/tolerability)
Level 1 Level 1 or 2 for efficacy and 1 for safety/tolerability
Level 2 Level 1 or 2 for efficacy and 2 for safety/tolerability
Level 3 Level 3 for efficacy and 1 or 2 for safety/tolerability
Level 4 Level 4 for efficacy or 3 for safety/tolerability
Level 5 Level 5 for efficacy (not recommended)
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treatment options used but ignores other important details, 
including duration. It includes the following stages: Stage I: 
failed monotherapy trial of lithium, anticonvulsant, or atyp-
ical antipsychotic of adequate dose and for adequate dur-
ation (FDA-approved treatment based on mood episode); Stage 
II: Stage I  plus failed trial of combination of 2 medications, 
lithium, or anticonvulsant and atypical antipsychotic; Stage III: 
Stage II plus failed trial of several different evidence-based ad-
junctive pharmacological compounds; and Stage IV: Stage III 
plus neurostimulation (Gajwani, 2009). Resistant BD-I or BD-II 
depression was defined in a stepped way as failure to reach re-
mission with adequately dosed lithium (0.8 mEq/L) or to other 
adequate ongoing mood-stabilizing treatment, plus lamotrigine 
(50–200 mg/d) or with full dose (600 mg/d or more) of quetiapine 
as monotherapy (Pacchiarotti et al., 2009)
To date, the International Society for Bipolar Disorders no-
menclature and definitions are the most comprehensive and up 
to date and utilize both a syndromal (on the basis of DSM cri-
teria) and symptomatic (on the basis of rating scales) approach. 
These definitions recommend the use of incremental steps for 
symptom improvement (<25%, 25–49%, 50–74%, 75–100%) to 
define response. They propose multiple cut-off points for the 
definition of remission, with the most stringent being <6 for 
Hamilton Depression Rating Scale (HDRS)-17 and Montgomery-
Asberg Depression Rating Scale (MADRS) and <5 for the Young 
Mania Rating Scale (YMRS) in the case of depression and mania, 
respectively. These stringent criteria allow for inclusion of 
subsyndromal states that are very important for failing func-
tional recovery in BD (7–14 in HDRS or MADRS and 8–14 in 
YMRS). In essence, the definition of subsyndromal states is 
utilized also for the definition of Treatment Emergent Affective 
Switch. Non-criterion symptoms that are commonly associated 
with BD (usually during the depressive phase) such as anxiety, 
panic attacks, irritability, hopelessness, avoidance, or cognitive 
dysfunction should not be included in the definitions. These au-
thors defined “recovery” as sustained remission after at least 8 
weeks (Tohen et al., 2009), which is similar to the approach of 
the AMA (American Psychiatric Association, 2000). A modified 
version was proposed several years later (Fountoulakis, 2012).
Another proposal was that treatment-resistant BD should 
be conceptualized as failure to respond to at least 2 trials of 
dissimilar medication with presumably adequate doses and 
durations within a specific phase of bipolar illness (manic, de-
pressive, or mixed) or for “breakthrough”; symptoms. These 
symptoms should emerge despite previous apparently effective 
maintenance treatment. There do not refer to patients who are 
intolerant (In table 4, the grading of treatment options according 
to safety issues is shown) of a treatment regimen and because of 
this they refrain from treatment and also to the extent possible, 
they do not refer to those patients who are not adherent to re-
commended treatment (Poon et al., 2012).
Τhe most recent attempt was to define treatment resistance 
in terms of failure to reach sustained symptomatic remission for 
8 consecutive weeks after 2 different treatment trials, at adequate 
Table 3. The CINP definitions of response, remission, recovery, and resistance for BD
Phase Scale scores
Treatment duration according  
to CINP guidelines
Response Acute mania <25%, 25–49%, 50–74%, 75–100% reduction in YMRS or MRS scores  
No significant increase in MADRS or HDRS scores and MADRS and 
HDRS scores stay below 6
8–10 weeks
 Acute Bipolar 
depression
<25%, 25–49%, 50–74%, 75–100% reduction in MADRS or HDRS  
scores  
No significant increase in YMRS or MRS scores and YMRS and MRS 
scores stay below 5
10–12 weeks
 Maintenance Significant change in the frequency of episodes 1 year
Remission Acute mania YMRS and MRS scores stay below 5  
No significant increase in MADRS or HDRS scores and MADRS and 
HDRS scores stay below 6
8 weeks
 Acute Bipolar 
depression
MADRS and HDRS scores stay below 6  
No significant increase in YMRS or MRS scores and YMRS and MRS 
scores stay below 5
8 weeks
 Maintenance Very rare new episodes, and MADRS/HDRS scores <6 and  
YMRS/MRS scores <7 between episodes
2–3 years?
Recovery Acute mania YMRS and MRS scores stay below 5  
No significant increase in MADRS or HDRS scores and MADRS and 
HDRS scores stay below 6
8 weeks
 Acute Bipolar 
depression
MADRS and HDRS scores stay below 6  
No significant increase in YMRS or MRS scores and YMRS and MRS 
scores stay below 5
8 weeks
 Maintenance No new mood episodes and MADRS/HDRS scores <6 and  
YMRS/MRS scores <7 between episodes
3–5 years
Resistance Acute mania No significant reduction in YMRS or MRS scores, or significant increase 
in MADRS or HDRS scores or MADRS and HDRS scores exceed 6
8–10 weeks
 Acute Bipolar 
depression
No significant reduction in in MADRS or HDRS scores or significant 
increase in YMRS or MRS scores or YMRS and MRS scores exceed 5
10–12 weeks
 Maintenance No change in the frequency of episodes, or MADRS/HDRS scores >6 or 
YMRS/MRS scores >7 between episodes
1 year
Abbreviations: BD, bipolar disorder; HDRS, Hamilton Depression Rating Scale; MADRS, Mondgomery-Asberg Depression Rating Scale; MRS, Mania Rating Scale; YMRS, 
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Table 4. Grading of treatment options according to safety issues following system shown in Table 1
Agent/modality  Grade Comments
Agomelatine 2 Elevation of liver enzymes 
Allopurinol 2 Swelling of mouth and lips, severe skin rashes, infections, eye irritation, hepatitis, appetite and weight loss, and 
painful or bloody urination
Amitriptyline 2 Many adverse effects, some risk for cardiovascular events
Aripiprazole 1  
Armodafinil/modafinil 2 Stimulant, risk for abuse
Asenapine 1  
Bupropion 1  
Carbamazepine 2 Hepatic enzymes induction, many adverse effects
Cariprazine 1  
Celecoxib 1  
Choline  Food supplement
Chromium  Food supplement
Clozapine 3 Potentially lethal agranulocytosis, metabolic syndrome
DBS 1  
Diltiazem 1  
Donepezil 1  
ECT 2 Not preferred by patients, mild cognitive problems
Folic acid  Food supplement
Gabapentin 1  
Galantamine   
Haloperidol 2 Extra-pyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, switch risk
Imipramine 2 Cardiac side effects, many adverse effects, switch risk
Inositol   
Ketamine 3 Transient dissociation and elevation of blood pressure
Lamotrigine 2 Good overall tolerability but potentially lethal skin reaction that can be avoided by slow titration
Levetiracetam 3 Induction of suicidality
Light therapy   
Lisdexamfetamine 3 High risk for abuse and dependence
Lithium 2 Many adverse effects, weight gain, toxicity
Lovastatin   
L-sulpiride 1  
l-thyroxine 2 Mild cardiovascular, skin and bone adverse effects
Lurasidone 1  
Magnesium  Food supplement
Memantine 1  
Modafinil 2 Stimulant, risk for abuse
n-3 fatty acids  Food supplement
N-acetyl cysteine 1  
Nimodipine 1  
Olanzapine 2 Metabolic syndrome
Omega 3 fatty acids 1  
Oxcarbazepine 1  
Paliperidone 1  
Paroxetine 1 Weight gain
Phenytoin 2 Many adverse effects
Pioglitazone 2 Not recommended in patients with diabetes mellitus type I and in liver disease Absolute contraindication in heart 
failure patients
Pramipexole 2 Adverse effects include the induction of compulsive behaviors and psychotic symptoms
Pregabaline 2 Risk of abuse, weight gain
Pregnenolone 2 Not well studied
Primidone   
Quetiapine 1 Weight gain
Ramelteon 1  
Risperidone/RLAI 1 Increased prolactin, weight gain
S-adenosyl-L-methione 2 Some adverse effects; long-term effects unknown
Sleep deprivation 1  
TMS 1  
Topiramate 3 Induction of depression and suicidality
Tranylcypromine 2 Many adverse effects
Tryptophan  Food supplement
Valnoctamide 1  
Valproate 1 Cautious use in women of childbearing age
Venlafaxine 2 Switch risk
Verapamil 1  
Ziprasidone 2 QTc prolongation, patient ECG recommended when used in combination
Abbreviations: DBS, deep brain stimulation; ECG, electrocardiogram; ECT, electroconvulsive therapy; EPS, extrapyramidal signs; RLAI, risperidon long acting injection; 
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therapeutic doses, with at least 2 recommended monotherapy 
treatments or at least 1 monotherapy treatment and another com-
bination treatment. It also introduced the term “multi-treatment-
resistant BD” after failure of additional trials with at least 1 trial 
with an antidepressant, a psychological treatment, and a course of 
electroconvulsive therapy (ECT) (Hidalgo-Mazzei et al., 2019).
Considering the above, the International Society for Bipolar 
Disorders definition is a good starting point, but the authors sug-
gest that additional considerations are necessary. The key points 
the therapist needs to consider before suggesting a patient might 
be treatment-resistant are summarized in Table 2. The proposed 
CINP definitions of response, remission, recovery, and resistance 
for BD are shown in Table 3. According to the authors of the cur-
rent paper, a key issue is that nonresponse should be considered 
only after treatment according to the best evidence available. At 
this time, the options recommended by the CINP guidelines for BD 
(Fountoulakis et al., 2017a, 2017b, 2017c, 2017d) and the CANMAT 
Guidelines (Yatham et al., 2018) provide the most up-to-date and 
comprehensive overview of treatment options.
Clinical Correlates of Treatment Resistance (n = 19)
A number of studies suggest that some kind of progression 
occurs over the long-term course of the illness, and this, in 
turn, contributes to treatment resistance (Berk et  al., 2011b; 
Fries et al., 2012) with an association to number of mood epi-
sodes (Swann et al., 1999; Obrocea et al., 2002; Scott et al., 2006; 
Reinares et al., 2010; Berk et al., 2011a; da Costa et al., 2016) and 
hospitalizations (Nunez et al., 2018). This progression is not uni-
form (Swann et al., 1999; Scott et al., 2006).
Table 5. Levels of recommendation concerning adjunctive treatment for resistant acute mania and recommended dosages for medication 
options
Treatment modality to add
Grading
In terms of efficacy In terms of recommendation Dosage
Aripiprazole 2 1 Up to 30 mg/d
Asenapine 2 1 Up to 20 mg/d
Quetiapine 1 1 Up to 800 mg/d
Valnoctamide 2 1 1200 mg/d
Haloperidol 2 2 Up to 12 mg/d
Olanzapine 2 2 Up to 40 mg/d
Phenytoin 3 3 400 mg/d
Allopurinol 4 4 600 mg/d
Carbamazepine 4 4 Up to 1200 mg/d
Clozapine 4 4 Up to 550 mg/d
ECT 4 4 –
Folic acid 4 4 3 mg/d
Leviracetam 4 4 2000–3000 mg/d
l-Thyroxine 4 4 Until FT4 higher than upper limit
Oxcarbazepine 4 4 Up to 1200 mg/d
Pregabaline 4 4 75–150 mg/d
Donepezil NR NR  
Gabapentin NR NR  
Lamotrigine NR NR  
Lovastatin NR NR  
Nifedipine NR NR  
Paliperidone NR NR  
Ramelteon NR NR  
Risperidone NR NR  
Topiramate NR NR  
Verapamil NR NR  
Ziprasidone NR NR  
Abbreviations: ECT, electroconvulsive therapy; FT4, free-T4; NR, not recommended.
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Clinical characteristics of treatment-resistant patients 
are the frequent presence of rapid cycling (37%), other forms 
of cycling (32%), chronic depression (26%), mixed states (6%) 
(Cole et al., 1993), and anxiety (Wooderson et al., 2014; Parker and 
Graham, 2017; Nunez et al., 2018). Other features include mel-
ancholia, comorbidity with social phobia, current suicidal risk 
and severe intensity of current depressive episode (Mendlewicz 
et al., 2010), cognitive difficulties, and sleep disturbance (Kessler 
et al., 2013; Wooderson et al., 2014). However, some studies failed 
to identify such clinical markers of resistance (Vo and Dunner, 
2003; Amsterdam et al., 2016a; Sandu et al., 2017)
Other features that might distinguish between resistant 
and nonresistant BD include being female, older, older age at 
illness onset, a higher incidences of family depression, lower 
likelihood of being gainfully employed, a higher number of life-
time stressors, medical conditions, a different personality and 
temperament profile, and more regular use of benzodiazepines 
(Parker and Graham, 2017). It is believed that substance use and 
unhealthy lifestyle might contribute to treatment resistance, al-
though data are lacking (Schaffer et al., 2017).
It is important that those clinical variables with supposed 
value in predicting response or resistance to lithium treatment 
and including the presence of elation, grandiosity, paranoia, 
irritability, delusions, and hallucinations did not predict treat-
ment response to lithium (Miller et al., 1991).
Overall, the data are of low quality and it is unknown whether 
the clinical picture is useful in predicting treatment response.
Neurobiological Correlates of Treatment Resistance (n = 3)
Only 3 studies reported on possible neurobiological correl-
ations of treatment resistance and identified family history of 
affective disorder (Cole et  al., 1993; Parker and Graham, 2017) 
and electroencephalographic abnormalities (Cole et  al., 1993) 
as risk factors, while neuroinflammation mechanisms seem to 
promote the progression towards treatment resistance (Bauer 
et al., 2017)
Treatment of Resistant BD 
Resistant Acute Mania (n = 62)
Double Blind Studies in the Treatment of Resistant Acute Mania (n = 26)
Valproate monotherapy (serum levels 50 and 100 mg/L), in 36 lithium-
resistant manic patients (including patients who could not tolerate 
lithium), produced a 54% decrease in scores on the YMRS in the val-
proate arm vs a 5% decrease in the placebo arm (Pope et al., 1991)
In 1 underpowered study, 13 BD-I and 15 BD-II patients re-
ceived 900–4800  mg/d gabapentin, lamotrigine, or placebo in 
a crossover design for 6 weeks, and at endpoint there was no 
difference between the 3 arms (Frye et  al., 2000). In another 
study, 114 BD-I outpatients resistant to lithium, valproate, or 
their combination were randomized to adjunctive gabapentin 
(600–3600 mg/d) or placebo for up to 10 weeks, with placebo per-
forming better (Pande et al., 2000).
There are positive data on add-on phenytoin in patients 
resistant to haloperidol treatment (Mishory et  al., 2000) and 
of add-on 600–1200  mg/d carbamazepine or oxcarbazepine in 
patients resistant to lithium (Juruena et al., 2009). The second 
study was of poor quality. A study adding lovastatin to lithium 
was negative (Ghanizadeh et al., 2014).
In patients resistant to lithium, valproate, or carbamazepine, 
it is beneficial to add olanzapine, quetiapine, aripiprazole, or 
asenapine (Tohen et al., 2002; Sachs et al., 2004; Yatham et al., 
2007b; Vieta et al., 2008; Szegedi et al., 2012) but not ziprasidone, 
topiramate, or paliperidone (Roy Chengappa et  al., 2006; 
Berwaerts et al., 2011; Sachs et al., 2012a, 2012b). For patients re-
sistant to both lithium and carbamazepine monotherapy, their 
combination was reported to be beneficial (at dosages corres-
ponding to lithium levels 0.7–1.2 mmol/L and up to 1600 mg/d of 
carbamazepine) (Kramlinger and Post, 1989).
One study provided inconclusive data for risperidone 
(Yatham et al., 2003b) as the results were likely confounded by 
the effects of carbamazepine on serum levels of risperidone.
There was only 1 sham-controlled trial of ECT as adjunctive 
treatment to chlorpromazine (600 mg/d) in 30 acutely manic pa-
tients and supported the efficacy of ECT with a faster rate of 
improvement (Sikdar et al., 1994).
One placebo-controlled 4-week random controlled trial in 
180 acutely manic patients supported the efficacy and safety 
of allopurinol (600  mg/d) and dipyridamole (200  mg/d) as ad-
junctive to lithium (Machado-Vieira et  al., 2008). However, a 
previous study was negative in patients resistant to lithium, 
valproic acid, carbamazepine, or atypical antipsychotic medica-
tions (Fan et al., 2012). Findings for valproate are inconclusive 
(Fan et al., 2012; Jahangard et al., 2014).
Folic acid was reported useful as an adjunct to valproate; 
however, the study is problematic concerning its methods 
of analysis and the reporting of results (Behzadi et  al., 2009). 
Valnoctamide (the valproic acid precursor) plus risperidone 
combination was more effective than risperidone plus placebo 
(Bersudsky et al., 2010), while a pilot 8-week study in 21 acutely 
manic outpatients on the usefulness of adjunctive ramelteon 
states failed (McElroy et al., 2011) and another 2 on donepezil 
were negative (Eden Evins et al., 2006; Chen et al., 2013).
Open Label Studies in the Treatment of Resistant Acute Mania (n = 23)
Treating resistant manic patients with olanzapine 5–40  mg/d 
monotherapy resulted in remission in three-quarters of patients 
(McElroy et al., 1998; Chen et al., 2011), and several small studies 
support the efficacy of up to 550  mg/d clozapine with three-
quarters of the patients responding after prolonged treatment 
(Kimmel et  al., 1994; Calabrese et  al., 1996; Ciapparelli et  al., 
2000; Green et al., 2000). The combination of aripiprazole with 
clozapine in BD patients that failed to respond to other atypical 
antipsychotics returned a positive result in psychotic manic pa-
tients (Benedetti et al., 2010). Results concerning risperidone are 
equivocal (Sajatovic et al., 1996; Vieta et al., 1998)
Adding gabapentin or pregabalin (600–3600 mg/d) resulted in 
response in three-quarters of resistant manic patients (McElroy 
et al., 1997; Altshuler et al., 1999; Schaffer et al., 2013). Only one-
quarter of rapid cycling patients responded (Altshuler et  al., 
1999). Adding 100–300 mg/d topiramate resulted in a response 
rate of almost 60% (Chengappa et al., 1999; Vieta et al., 2002b) 
but titrating up to 1300  mg/d did not increase the response 
(Calabrese et al., 2001). Adding leviracetam (500–1000 mg/d) pro-
duced response or remission in one-half of patients (Post et al., 
2005); data concerning verapamil (up to 240 mg/d) were negative 
(Barton and Gitlin, 1987) while for nifedipine 120 mg/d were un-
impressive (De Beaurepaire, 1992). Some positive findings exist 
for diltiazem (Silverstone and Birkett, 2000). Adding l-thyroxine 
to lithium or carbamazepine resulted in a 50% response rate 
(Bauer and Whybrow, 1990).
Three-quarters of resistant manic patients respond to ECT 
(Perugi et al., 2017) with equal efficacy for unilateral vs bilateral 
ECT (Mukherjee et al., 1988), and bifrontal ECT was as efficacious 
as bitemporal ECT and better tolerated (Barekatain et al., 2008; 
Hiremani et al., 2008).
Meta-Analytic and Review Studies in the Treatment of Resistant Acute 
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Meta-analytic studies also suggest that combination treatment 
is superior to monotherapy at the cost of more frequent adverse 
events; however, these meta-analyses do not distinguish be-
tween add-on studies (which utilize patients resistant to mono-
therapy) and combination studies (which utilize general patient 
populations) (Scherk et al., 2007; Smith et al., 2007; Tarr et al., 
2011; Ogawa et al., 2014). Due to the insufficient evidence base, 
earlier reviews provide only vague conclusions (Gitlin, 2001, 2006; 
Keck and McElroy, 2001). Overall, there is a striking paucity of re-
search concerning resistant cases, and existing studies are small 
and insufficiently controlled and findings remain preliminary. 
ECT is generally considered as an option for resistant patients. 
In acute manic patients who are partial responders to lithium/
valproate/carbamazepine, adding an antipsychotic is a reason-
able choice. Encouraging results have been reported by adding 
aripiprazole, clozapine, and pregabalin in resistant mania (Hui 
Poon et al., 2015). The analysis of the data for the cholinesterase 
inhibitors galantamine and donepezil as well as the glutamate 
receptor antagonist memantine was negative (Veronese et  al., 
2016). One meta-analysis of combination studies confirmed 
the higher rate of adverse events compared with monotherapy 
(Galling et al., 2015). One review of open studies supported the 
usefulness of clozapine (Li et al., 2015).
There are a few randomized controlled trials of ECT in mania, 
and they consistently report clinically meaningful efficacy, with 
a majority of pharmacotherapy-resistant patients responding to 
ECT. Evidence for the use of other brain stimulation therapies 
in treating bipolar mood states is preliminary and limited (Loo 
et al., 2011; Versiani et al., 2011).
Conclusion Concerning the Treatment of Resistant Acute Mania
Controlled data suggest that in patients resistant (principally) 
to lithium, valproate, or carbamazepine, it is beneficial to add 
aripiprazole, asenapine, folic acid, quetiapine, or valnoctamide. 
The next choice should be adding haloperidol, olanzapine, or 
phenytoin on lithium, valproate, or carbamazepine. The data 
are inconclusive concerning allopurinol, carbamazepine, clo-
zapine, ECT, leviracetam, l-thyroxine, oxcarbazepine, and 
pregabalin.
According to controlled data, the agents not recom-
mended include donepezil, gabapentin, lamotrigine, lovastatin, 
paliperidone, ramelteon, risperidone, topiramate, and 
ziprasidone, while additionally, on the basis of open data, nifedi-
pine and verapamil are also not recommended (Table 5; Figure 2).
Mixed Episodes (n = 7)
Adding olanzapine or placebo to divalproex-resistant mixed pa-
tients for 6 weeks returned positive results both for the manic 
as well as for the depressive component (Houston et al., 2009). 
One open study of adjunct gabapentin (300–2000 mg/d) re-
ported an almost 50% response rate but this concerned exclu-
sively the depressive component (Perugi et al., 1999).
There were no randomized trials of ECT in mixed episodes 
(Loo et al., 2011). The results of open trials concerning the useful-
ness of ECT suggest that approximately 40% to two-thirds of pa-
tients responded and 30% remitted, and the response concerned 
both the manic and the depressive components (Medda et al., 
2010, 2015; Perugi et al., 2017). One study concerning repetitive 
transcranial stimulation (rTMS) reported a lower response rate 
(around 40%) and response restricted to the depressive compo-
nent (Pallanti et al., 2014).
Treatment-Resistant BD (n = 145)
Double Blind Studies in the Treatment of Resistant Acute BD (n = 69)
In bipolar depressed patients who experience depression while 
under lithium treatment, it is appropriate to add lamotrigine 
(van der Loos et  al., 2009, 2010, 2011), the D2 antagonist 
L-sulpiride (Bocchetta et al., 1993), pramipexole (Goldberg et al., 
2004), or possibly oxcarbazepine (Juruena et al., 2009) but not im-
ipramine (Nemeroff et al., 2001). The data on adding paroxetine 
and amitriptyline are equivocal (Bocchetta et  al., 1993; Bauer 
et  al., 1999; Young et  al., 2000; Pilhatsch et  al., 2010; van der 
Loos et al., 2010). Imipramine and venlafaxine might pose the 
patients at an increased risk of switching without a superior 
benefit compared with other antidepressants (Nemeroff et al., 
2001; Vieta et al., 2002a); however, 1 study suggests quite the op-
posite (Amsterdam et al., 2016b). One study suggested that the 
addition of lamotrigine to quetiapine treatment improved out-
comes, but folic acid seems to nullify the effect of lamotrigine 
(Geddes et al., 2016).
In BD patients experiencing depression during treatment 
with lithium or valproate, ketamine or lurasidone could be 
added. Lurasidone also improves anxiety (Loebel et al., 2014) and 
ketamine improves suicidality. Response to a single ketamine 
infusion may appear within hours but does not last more than 
3 to 4 days (Diazgranados et al., 2010; Zarate et al., 2012; Lally 
et al., 2014; Loebel et al., 2014; Xu et al., 2015). One study reported 
negative results (Xu et  al., 2015). Besides reducing suicidality, 
ketamine has been reported to be efficacious especially against 
anhedonia (Lally et al., 2014) and fatigue (Saligan et al., 2016). 
Repeated administration of ketamine studies have not been car-
ried in BD (Murrough et al., 2013; Phillips et al., 2019). There is 1 
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failed study with lurasidone as add-on to lithium or valproate 
(Suppes et al., 2013, 2016).
An underpowered placebo-controlled adjunctive study of 
aripiprazole to lithium and citalopram was negative (Quante 
et al., 2010).
For a depressed episode during treatment with mood stabil-
izers, it is not beneficial to add ziprasidone (Sachs et al., 2011; 
Patkar et  al., 2015). Topiramate and levetiracetam should be 
avoided because of a risk of worsening depression and inducing 
suicidality (CIT0371). Imipramine and venlafaxine increased the 
risk of switching without superior benefits compared with other 
antidepressants (Sachs et al., 1994, 2011; Post et al., 2001, 2006; 
Shelton and Stahl, 2004; Schaffer et  al., 2006; Altshuler et  al., 
2009; Saricicek et al., 2011).
The data are negative concerning the addition of 
memantine on lamotrigine (Anand et  al., 2012) or valproate 
(Lee et  al., 2014a, 2014b), ketamine on ECT (Abdallah et  al., 
2012), lisdexamfetamine to treatment as usual (TAU) (McElroy 
et al., 2015), and agomelatine to lithium or valproate (Yatham 
et al., 2016).
A study in 85 patients with adjunctive modafinil (mean 
dosage 177 mg/d) was positive without switching to mania or 
hypomania. Response and remission rates were higher in the 
modafinil group (44% and 39%) compared with the placebo group 
(23% and 18%) (Frye et al., 2007). However, modafinil could cause 
subclinical switches (Fountoulakis et al., 2008b). One published 
study for the treatment of acute BD-I depression with adjunct 
armodafinil (dosage 150 mg/d; n = 128) to lithium, valproate, or 
olanzapine was positive (Calabrese et al., 2010, 2014). However, 2 
other studies were negative (Ostacher, 2014; Ketter et al., 2015).
One small study on pioglitazone as add-on to lithium 
in bipolar patients without diabetes mellitus was positive 
(Zeinoddini et al., 2015). A trial of celecoxib (400 mg/d) was nega-
tive in the treatment of depressive or mixed episodes (Nery 
et  al., 2008). One study with add-on pregnenolone (titrated to 
500 mg/d) was negative (Brown et al., 2014). While a very small 
report without an a priori defined primary outcome suggested 
that adding supraphysiologic doses of levothyroxine (L-T4) to 
a mood stabilizer improves the outcome (Bauer et al., 2016), a 
previous, more complete report on the same placebo-controlled 
dataset was negative (Stamm et al., 2014). That study reported 
positive findings in females but not in males. A  small quasi-
placebo-controlled study was positive concerning the addition 
of inositol (Chengappa et al., 2000).
A 24-week trial on the efficacy of N-acetyl cysteine (NAC, 1 g 
twice daily) adjunctive to usual medication in subsyndromal but 
treatment-resistant depressive symptoms was positive (Berk 
et al., 2008); however, a more recent study was negative (Berk 
et al., 2019a, 2019b). The data on omega-3 fatty acids are con-
flicting and inconclusive (Stoll et al., 1999; Frangou et al., 2006, 
2007; Keck et al., 2006; Murphy et al., 2012). One negative study 
exists concerning S-adenosyl-L-methione up to 1400  mg/d 
(Murphy et al., 2014).
ECT may be more effective than pharmacotherapy for 
treatment-resistant bipolar depression (Schoeyen et  al., 2015) 
but TMS is poorly investigated in bipolar depression (Dell’Osso 
et al., 2009). Active deep TMS was superior to sham at end point 
(P = .03) but not at follow-up (Tavares et al., 2017). One study on 
transcranial direct current stimulation reported that the cumu-
lative response rates were higher in the active vs sham groups 
(67.6% vs 30.4%; P = .01) but not remission rates (37.4% vs 19.1%; 
P = .18) (Sampaio-Junior et al., 2018).
Sleep deprivation and other noninvasive circadian-related 
interventions could be useful add-on treatments to accelerate 
and sustain the antidepressant response (Wu et  al., 2009). 
A study on bright light therapy in bipolar depression was nega-
tive (Dauphinais et al., 2012), whereas other controlled studies 
were positive (Sit et al., 2018; Yorguner Kupeli et al., 2018; Zhou 
et al., 2018).
Open Label Studies in Treatment of Resistant Acute Bipolar Depression 
(n = 32)
One study reported a 31% response rate with add-on 
levetiracetam titrated to a target dose of 2000 mg/d (Post et al., 
2005). Another study supported the adjunctive therapy with 
diltiazem (Silverstone and Birkett, 2000).
Adding bupropion to ongoing treatment after 4 weeks 
yielded a 60% response (Erfurth et  al., 2002) while adding 
tranylcypromine in imipramine-resistant patients resulted in a 
75% response (Thase et al., 1992).
Resistant depressive patients from the STEP-BD trial were 
randomly assigned to open-label adjunctive treatment with 
lamotrigine, inositol, or risperidone for up to 16 weeks without 
any significant between-group differences. However, the re-
covery rate with lamotrigine was 23.8% vs 17.4% with inositol 
and 4.6% with risperidone (Nierenberg et  al., 2006). Another 
STEP-BD subgroup received adjunctive aripiprazole, but the re-
sponse rate was as low as 27% (Ketter et al., 2006).
Adjunctive gabapentin for 12 weeks (mean dose 1725 mg/d) 
resulted in a 55% response (Wang et al., 2002) and for 8 weeks 
with mean dosage 1270  ± 561  mg in a 42% response rate 
(Perugi et al., 2002). A third very small trial (n = 5) reported that 
all patients responded to adjunctive gabapentin (Altshuler 
et al., 1999).
Adding lamotrigine 75–100  mg/d resulted in an approxi-
mately 50–70% response (Kusumakar and Yatham, 1997; 
Nierenberg et al., 2006; Kagawa et al., 2014).
Adding levetiracetam up to 3000 mg/d resulted in 31% remis-
sion (Post et al., 2005). Approximately 23% of patients from the 
Stanley Foundation Bipolar Network long-term follow-up study 
responded after adding 8.7  mg/d of tiagabine (Suppes et  al., 
2002) and one-half of patients responded to topiramate (Vieta 
et  al., 2002b). Two-thirds of patients responded to 0.95  mg/d 
pramipexole (Lattanzi et al., 2002).
There were 3 positive papers (2 on the same dataset) on 
the utilization of a single infusion of ketamine (0.5 mg/kg) over 
40 min resulting in a 50% response (Rybakowski et al., 2013, 2017; 
Ionescu et al., 2015). One small study was positive for omega-3 
fatty acids (Chiu et al., 2005).
More than one-half of patients and two-thirds of those with 
BD-I are reported to respond to ECT (Medda et al., 2009, 2010; 
Perugi et al., 2012, 2017; Schoeyen et al., 2015) while one-fourth 
manifest remission (Medda et al., 2010). One study, however, re-
ported similar remission rates with an algorithm-based pharma-
cological treatment (34.8% vs 30.0%) (Schoeyen et  al., 2015). 
Another study with nonconvulsive electrotherapy reported 73% 
response and 55% remission rates (Regenold et al., 2015).
Early rTMS studies reported a 60% response rate (Dell’Osso 
et al., 2009; Wozniak-Kwasniewska et al., 2015). One study of se-
quential bilateral rTMS vs sham treatment was negative with 
both arms having a 10% response rate (Fitzgerald et al., 2016), 
but another with high-frequency repetitive transcranial mag-
netic stimulation reported 35% response and 30% remission 
rates (Poleszczyk et al., 2018).
The results with deep brain stimulation in a very small 
study were rather poor (<20% acute response and remission 
rates) (Holtzheimer et al., 2012), and similarly a study with deep 
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was superior at week-4 in HDRS but not at follow-up at week-
8. There was no difference in response and remission rates 
(Tavares et al., 2017). An earlier H1-Coil rTMS study reported that 
two-thirds of patients responded and one-half of them remitted 
(Harel et al., 2011).
Total sleep deprivation plus light therapy for 1 week resulted 
in a 44% response in resistant patients (Benedetti et al., 2005).
Post-hoc, Review, and Meta-Analytic Studies (n = 48)
The problems in the literature concerning the treatment of 
resistant bipolar depression are described in several reviews 
and meta-analytical studies. The overall conclusion is that the 
available hard data are extremely scarce and most of the strat-
egies remain essentially experimental; however, there seem to 
be some that are potentially efficacious and promising (Aan 
Het Rot et al., 2012; Poon et al., 2012; Sienaert et al., 2013; Hui 
Poon et  al., 2015). In addition, combination studies confirmed 
the higher rate of adverse events compared with monotherapy 
(Galling et al., 2015).
Existing papers suggest minimal effects of lamotrigine, 
risperidone, inositol (Parikh et al., 2010), or lurasidone (Sanford 
and Dhillon, 2015) and that the addition of an antidepressant 
does not increase efficacy (Parikh et  al., 2010; Van Lieshout 
and MacQueen, 2010). The combination with best data in re-
sistant acute bipolar depression is lithium plus lamotrigine 
(Fountoulakis et al., 2012c). Antidepressant reviews provide con-
flicting conclusions (Gijsman et al., 2004; Sidor and Macqueen, 
2011; Vazquez et al., 2013; Zhang et al., 2013); 1 meta-analysis was 
negative regarding the usefulness of galantamine, donepezil, 
and memantine (Veronese et al., 2016) while another concluded 
that second-generation antidepressants produced a significant 
but small score change but had no effect in response and re-
mission rates. There was also no increased risk of treatment-
emergent mania or hypomania during the acute phase while 
there was some risk in the long term (McGirr et al., 2016a).
Some studies support the efficacy of stimulants, espe-
cially modafinil and armodafinil (Corp et  al., 2014), ketamine 
(Corp et  al., 2014; Fond et  al., 2014; McGirr et  al., 2015), and 
Table 6. Levels of recommendation concerning adjunctive treatment for resistant acute bipolar depression and recommended dosages for 
medication options
Treatment modality to add
Grading
In terms of efficacy In terms of recommendation Dosage 
Lamotrigine (on lithium) 1 2 Up to 200 mg/d
Light therapy 1 1  
ECT 2 2  
Modafinil 2 2 Up to 200 mg/d
Pramipexole 2 2 Up to 2.5 mg/d
TMS 2 2  
Pioglitazone 3 3 30 mg/d
Amitriptyline 4 4 Up to 150 mg/d
Bupropion 4 4 Up to 375 mg/d
Clozapine 4 4 Up to 600 mg/d
Diltiazem 4 4 Up to 240 mg/d
Gabapentin 4 4 600–2400 mg/d
L-sulpiride 4 4 50–75 mg/d
N-acetyl cysteine 4 4 2000 mg/d
Ketamine 1 4 Intravenous infusion 0.5 mg/kg
l-Thyroxine 4 4 300 mcg/d
Lurasidone 4 4 Up to 120 mg/d
Omega-3 fatty acids 4 4 Various
Oxcarbazepine 4 4 Up to 1200 mg/d
Paroxetine 4 4 Up to 40 mg/d
Pramipexole 4 4 3 mg/d
Sleep deprivation 4 4 –
Tranylcypromine 4 4 30–60 mg/d
Venlafaxine 4 4 75–225 mg/d
Agomelatine NR NR  
Aripiprazole NR NR  
Celecoxib NR NR  
DBS NR NR  
Galantamine NR NR  
Imipramine NR NR  
Inositol NR NR  
Leviracetam NR NR  
Lisdexamfetamine NR NR  
Memantine NR NR  
Pregnenolone NR NR  
S-adenosyl-L-methione NR NR  
Topiramate NR NR  
Ziprasidone NR NR  
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antiinflammatory agents (Rosenblat et  al., 2016). A  meta-
analytic study supported the efficacy of dopaminergic drugs 
(Szmulewicz et al., 2017). The review of pramipexole data sug-
gested that two-thirds of patients respond (Dell’Osso and Ketter, 
2013; Tondo et al., 2014).
The meta-analysis of ketamine studies supported its effi-
cacy but also suggested the data are conflicting as to whether 
the therapeutic effect extends beyond day 4 and up to day 7 
(Sienaert et al., 2013; Caddy et al., 2014; Fond and Boyer, 2014; 
Fond et al., 2014; Tondo et al., 2014; Coyle and Laws, 2015; Lee 
et al., 2015; McGirr et al., 2015; Newport et al., 2015; Parsaik et al., 
2015; Romeo et al., 2015; Bobo et al., 2016; Kishimoto et al., 2016; 
Saligan et al., 2016; Xu et al., 2016; Kraus et al., 2017).
One meta-analysis was positive concerning the usefulness of 
light therapy (Tseng et al., 2016).
Reviews and meta-analyses are positive concerning omega-
fatty acids, but they do not include all trials (Sarris et al., 2012; 
Sylvia et  al., 2013; Grosso et  al., 2014; Ciappolino et  al., 2017). 
Another meta-analysis was negative for adjunctive inositol 
(Mukai et al., 2014) and another one supported the usefulness of 
clozapine (Li et al., 2015).
There are no studies with adequate methodology on ECT 
(Loo et al., 2011; Versiani et al., 2011). One meta-analysis com-
pared the efficacy of ECT in unipolar vs bipolar depression and 
identified 6 relevant studies. It reported a similar rate of re-
sponse in both disorders (50.9% vs 53.2%) (Dierckx et al., 2012).
A meta-analysis of rTMS in bipolar depression, although 
based overall on a smaller number of participants, supported 
efficacy (McGirr et al., 2016b).
One post-hoc study pooled the data from transcranial direct 
current stimulation (transcranial direct current stimulation) 
trials and reported significant positive results (D’Urso et  al., 
2017) while a review suggested that Vagus nerve stimulation is 
promising for bipolar depression (Cimpianu et al., 2017). Another 
review focused on surgical interventions but without any con-
clusion (Lipsman et al., 2010).
Conclusion Concerning the Treatment of Resistant Acute Bipolar 
Depression
Controlled data suggest that in resistant bipolar depressive pa-
tients, it is beneficial to use lithium plus lamotrigine or adding 
lamotrigine, modafinil, or pramipexole. Ketamine is also an-
other option but carries the risk of transient dissociation and 
increased blood pressure. The data are inconclusive concerning 
L-sulpiride, amitriptyline, bupropion, clozapine, diltiazem, ECT, 
gabapentin, l-thyroxine, lurasidone, NAC, omega-3 fatty acids, 
oxcarbazepine, paroxetine, pramipexole, sleep deprivation, TMS, 
tranylcypromine, and venlafaxine.
According to either controlled or open data, the interventions 
not recommended include agomelatine, aripiprazole, celecoxib, 
deep brain stimulation, galantamine, imipramine, inositol, 
leviracetam, lisdexamfetamine, memantine, pregnenolone, 
S-adenosyl-L-methione, topiramate, and ziprasidone (Table  6; 
Figure 3).
BD Resistant to Maintenance Treatment (n = 49)
Double-Blind Studies in Maintenance Treatment of Resistant BD (n = 24)
A small study supported the adding of phenytoin to TAU 
(Mishory et al., 2003) as did another small one for gabapentin 
(but not on top of antipsychotics) (Vieta et  al., 2006). One 
study suggested a beneficial effect of clozapine on a small 
subsample of nonpsychotic BD (Suppes et al., 1999). Data are 
equivocal for the addition of lamotrigine to lithium (van der 
Loos et  al., 2011) and negative for adjunctive pramipexole 
to TAU in stabilized BD patients with the aim to improve 
neurocognition (Burdick et  al., 2012). Two studies suggest 
that Risperidone Long Acting Injectable (RLAI) on TAU signifi-
cantly prolongs the time to relapse (Macfadden et  al., 2009; 
Quiroz et al., 2010), as did adding aripiprazole (Marcus et al., 
2011) or ziprasidone (Citrome, 2010) to lithium or valproate. 
Adding aripiprazole to lamotrigine did not improve long-term 
outcome (Carlson et  al., 2012). Patients who responded to 
treatment with lithium, valproate, or carbamazepine plus 
antidepressants were more likely to maintain response with 
continuation of the combined treatment; however, those pa-
tients who manifested only a partial acute response were 
unlikely to further improve when the same treatment was 
continued (Altshuler et  al., 2009). Adjunctive asenapine to 
lithium or valproate was well tolerated for up to 52 weeks, but 
no efficacy data were reported from that trial due to lack of 
statistical power (Szegedi et al., 2012).
One trial in 75 BD patients reported that NAC treatment 
caused a significant improvement on the MADRS score com-
pared with placebo (P = .002) during maintenance. There was 
no effect of NAC on time to a mood episode and no significant 
between-group differences in adverse events (Berk et al., 2008). 
Another study in 14 BD-II patients from the previous study re-
ported a superiority of the NAC group vs placebo in terms of re-
mission (P = .031) (Magalhaes et al., 2011a). Data were conflicting 
concerning ramelteon (Norris et  al., 2013; Mahableshwarkar 
et al., 2017) and negative results for memantine in patients on 
valproate treatment (Lee et al., 2014b).
Figure 4. Algorithm for the treatment of resistant cases of bipolar disorder (BD) 
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There are some studies suggesting that there is a role for 
various nutritional supplements such as n-3 fatty acids (eicosa-
pentaenoic acid and docosahexaenoic acid), chromium, cho-
line, magnesium, and tryptophan alone or in combination with 
pharmacotherapies for the treatment of BD, but the data are of 
low quality (Sylvia et al., 2013).
Open-Label Studies in Maintenance Treatment of Resistant BD (n = 22)
Open studies support the usefulness of adding clozapine 
(Suppes et  al., 1999; Ciapparelli et  al., 2000, 2003), gabapentin 
(Schaffer and Schaffer, 1999), lamotrigine (Calabrese et al., 1999), 
levetiacetam (Post et al., 2005), RLAI (Yatham et al., 2007a), and 
the anticonvulsant primidone (Schaffer et  al., 1999) with ap-
proximately 30–40% of patients responding, while a higher than 
40% response rate was reported for olanzapine (McElroy et al., 
1998; Vieta et al., 2001), higher than 50% with L-thyroxine T(4) 
(Bauer et  al., 2002), and higher than 70% for the N-methyl-D-
aspartate antagonist memantine (Koukopoulos et al., 2010).
One-third of participants responded well to the combination 
of lithium plus valproate (Denicoff et al., 1997), but the BALANCE 
study neither supported nor refuted the superiority of the com-
bination of lithium plus valproate over monotherapy (Geddes 
et al., 2002; Rendell et al., 2004; Investigators et al., 2010). Results 
were somewhat positive also for the combination of carba-
mazepine plus nimodipine, but negative for adding the calcium 
channel blocker verapamil (Pazzaglia et al., 1998). For overweight 
patients, adding topiramate (McElroy et al., 2000; Lykouras and 
Hatzimanolis, 2004; Gabriel, 2007)or zonisamide (Wang et  al., 
2008) could be an option. However, mood destabilization was 
observed in another study with the addition of zonisamide.
Using maintenance ECT for more than 18  months, with a 
treatment at approximately monthly intervals, resulted in an up 
to 80% response rate (Vanelle et al., 1994).
Post-hoc, Review, and Meta-Analytic Studies (n = 10)
Meta-analyses support the efficacy of antidepressants added to 
mood stabilizers in the long-term treatment of bipolar patients 
without increasing risk of new manic/hypomanic episodes (Liu 
et  al., 2017). Ziprasidone plus lithium or valproate treatment 
showed modest to moderate remission rates at week 24 based 
on 4 different remission criteria in terms of symptomatic and 
sustained remission (Pae et al., 2012).
The addition of an atypical antipsychotic-antimanic agent in 
some BD patients might help to reduce suicidal ideation (Houston 
et al., 2006). Efficacy of NAC was also supported by 2 post-hoc ana-
lyses (Magalhaes et al., 2011b, 2013), which, however did not in-
clude more recent negative data. Two other studies supported the 
usefulness of RLAI (Bobo and Shelton, 2010) for the maintenance 
treatment of BD-I disorder in adults as an adjunct to lithium or 
valproate. One paper supported the usefulness of the dopamine 
agonist pramipexole (Dell’Osso and Ketter, 2013). Overall, the re-
view papers support the usefulness of ECT (Vaidya et al., 2003; 
Fountoulakis et al., 2012c), the combination of antiepileptics with 
antipsychotics (Fountoulakis et al., 2012c), and clozapine (Li et al., 
2015) for the maintenance treatment of resistant patients.
Conclusion Concerning Treatment for Resistant Patients During Main-
tenance Phase
Controlled data suggest that in resistant patients (principally to 
lithium, valproate, or carbamazepine), it is beneficial to add anti-
depressants, RLAI, aripiprazole, or ziprasidone to the ongoing 
treatment. The next choice should be adding gabapentin or 
phenytoin. The data are inconclusive concerning clozapine, ECT, 
leviracetam, lithium plus lamotrigine or valproate, L-thyroxine, 
the calcium blocker nimodipine, olanzapine, primidone, 
ramelteon, and the food supplements choline, chromium, mag-
nesium, n-3 fatty acids, and tryptophan.
Table 7. Levels of recommendation concerning adjunctive treatment for resistant patients during maintenance phase and recommended dos-
ages for medication options
Treatment modality to add
Grading
In terms of efficacy In terms of recommendation Dosage 
RLAI 1 1 Up to 100 mg/mo
Aripiprazole 2 2 Up to 30 mg/d
Ziprasidone 2 2 Up to 160 mg/d
Gabapentin 3 3 Up to >2500 mg/d
Phenytoin 3 3 380 mg/d
Choline 4 4 –
Chromium 4 4 –
Clozapine 4 4 Up to 600 mg/d
ECT 4 4 –
Leviracetam 4 4 Up to 3000 mg/d
Lithium plus lamotrigine or valproate 4 4 Usual recommended dosages
L-Thyroxine 4 4 500 μg/d
Magnesium 4 4 –
n-3 fatty acids 4 4 –
Nimodipine 4 4 Up to 360 mg/d
Olanzapine 4 4 Up to 30 mg/d
Primidone 4 4 Up to 250 mg/d
Ramelteon 4 4 8 mg/d
Tryptophan 4 4  
Aripiprazole plus lamotrigine NR NR  
Memantine NR NR  
N-acetyl cysteine NR NR  
Pramipexole NR NR  
Verapamil NR NR  
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According to either controlled or open data, the 
nonrecommended agents include memantine, NAC, 
pramipexole, and verapamil. Aripiprazole plus lamotrigine was 
also not effective (Table 7; Figure 4).
It is important to note that the scarcity of the data does not 
permit a differential choice between agents and treatment op-
tions to prevent the relapse into a manic or depressive episode 
preferentially.
Resistant Rapid Cycling Cases (n = 10)
The data on resistant patients with rapid cycling course are 
very few. Overall, they suggest that the combination of lithium 
plus divalproex for up to 16 weeks leads to only 14% stabiliza-
tion with no additional value of adjunct lamotrigine (Kemp 
et  al., 2012). One small trial of clorgyline 2.5–10.0  mg/d, alone 
or in combination with lithium carbonate, was positive (Potter 
et  al., 1982), while clozapine was found to be less efficacious 
in resistant rapid cycling patients (Suppes et al., 2004; Li et al., 
2015). On the contrary, lamotrigine as an add-on therapy exerted 
a similar effect in rapid and non-rapid cycling patients (Bowden 
et al., 1999). A small cross-over, double blind study was positive 
for adjunctive nimodipine (Pazzaglia et al., 1993).
Adding mexiletine 200–1200 mg/d led to 46% remission and 
15% partial response (Schaffer et al., 2000) while levothyroxine 
improved only depressive symptoms (Bauer and Whybrow, 
1990). Vagus nerve stimulation was associated with a 38.1% 
mean improvement in overall illness over a 12-month study 
period (Marangell et al., 2008). Adding chromium resulted in an 
acute response in one-third of patients, but only regarding de-
pression. The high drop-out rate made it impossible to test for 
maintenance efficacy (Amann et al., 2007).
Lithium Discontinuation-Induced Treatment Resistance (n = 10)
Treatment resistance possibly induced by lithium discontinu-
ation was suggested for the first time by Post et al following a 
systematic life-chart methodology in the study of 4 patients 
with BD in whom long periods (6–15 years) of effective lithium 
prophylaxis were followed by relapses on lithium discontinu-
ation. Once the drug was reinstituted, it was no longer effective 
(Post et  al., 1992). However, the reason for discontinuation in 
these 4 cases was not reported, and the discussion of these cases 
clearly leaves room for a progression of the illness rather than a 
specific lithium-related cause as the most probable explanation.
Case reports and selected reviews support this (Post et  al., 
1993; Bauer, 1994; Murray, 1994; Koukopoulos et  al., 1995; Maj 
et al., 1995; Tondo et al., 1997; Post and Leverich, 2008; Post, 2012) 
but the arguments are scientifically weak.
The only existing systematic review and meta-analysis of 
the literature identified the existence of 212 patient data rele-
vant to this question and the meta-analysis returned negative 
results, suggesting there is no convincing evidence that lithium 
is less effective when treatment is discontinued and restarted 
compared with uninterrupted treatment (de Vries et al., 2013).
Psychological Treatments (n = 21)
There are some but overall limited data of problematic quality 
concerning the usefulness of specific adjunctive psychotherapies 
(Reinares et al., 2014; Miziou et al., 2015).
Although the overall data for the long-term efficacy of 
cognitive-behavioral therapy (CBT) either as monotherapy or 
as add on to TAU are negative concerning relapse prevention, 
there are some positive results for the acute depressive phase 
in BD (Ball et al., 2006; Scott et al., 2006; Zaretsky et al., 2008; 
Costa et  al., 2011; Gomes et  al., 2011; Meyer and Hautzinger, 
2012; Gonzalez Isasi et  al., 2014). The effectiveness of psy-
chotherapy for resistant patients was reported to increase 
with time, and this improvement was not significant until 
12 months of follow-up (Gonzalez-Isasi et al., 2010, 2012; Isasi 
et al., 2010). A post-hoc analysis suggested that CBT could be 
more effective than TAU in patients with less than 12 previous 
episodes but less effective in those with more episodes (Scott 
et al., 2006). In BD patients with insomnia, CBT for insomnia 
was superior to psychoeducation concerning manic relapses 
(Harvey et al., 2015).
The data on adjunctive psychoeducation suggest that com-
pared with TAU or nonspecific intervention, it prevents relapse 
to both poles if administered to patients in clinical remission 
(Perry et al., 1999; Colom et al., 2003; Colom et al., 2009; Lobban 
et al., 2010; de Barros Pellegrinelli et al., 2013), but it has no ef-
fect on biological rhythms (Cardoso Tde et  al., 2015). Again, a 
post-hoc analysis suggested that patients with more than 7 
episodes did not show significant improvement with group 
psychoeducation for time to recurrence, and those with more 
than 14 episodes did not benefit from the treatment in terms of 
time spent ill (Colom et al., 2010). A systematic review confirmed 
the above (Bond and Anderson, 2015).
There are no data to support the usefulness of interpersonal 
and social rhythm therapy, family focus treatment, intensive 
psychosocial intervention, cognitive remediation and func-
tional remediation, mindfulness-based interventions (MBCT), 
or internet-based interventions in the treatment of resistant BD 
patients.
Overall, there are limited data to suggest that any kind of 
psychotherapy is useful in resistant BD patients; some data 
suggest that it could be useful in resistant patients at the early 
stages of the disorder.
Algorithm for Treatment of Resistant BD
A visual representation of the recommended steps in the 
treatment of resistant cases during each phase is shown in 
Figures  2–4. As already mentioned, this specific algorithm is 
based on the materials collected to develop a general algo-
rithm for BD by the CINP (Fountoulakis et  al., 2017a, 2017b, 
2017c, 2017d).
The authors decided that although mixed episodes are not 
included in DSM-5, it would be important to include a guid-
ance option for them since some relevant data do exist. Also, 
they decided to include a recommendation for adding CBT 
and/or psychoeducation at a level higher than the evidence 
suggests, because, if available, they could be added without 
problems to existing pharmacotherapy. However, the recom-
mendation is that this addition should not interfere with the 
application of the algorithm itself, that is, the first step of the 
algorithm concerning pharmacotherapy should always be ini-
tialized and pseudo-resistance should have been ruled out 
(Schaffer et al., 2017).
Discussion
The current guidelines are the first to our knowledge developed 
specifically for the treatment of resistant bipolar patients, and 
they also include an operationalized definition of treatment 
resistance.
The key issue is the definition of “response,” since this is 
a prerequisite for the definition of “resistant.” There are sev-
eral papers defining response, remission, and resistance in 
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characterized by a rather narrow and vague approach. With 
BD, these definitions face a particular problem. They perform 
well with disorders with a predominantly linear course, char-
acterized by exacerbations and remissions and with a single 
major factor or constellation of symptoms (e.g., unipolar mel-
ancholic depression). They also perform relatively well with 
complex disorders like schizophrenia that, in spite of the large 
variability of the clinical picture (to the extent it is possible 2 
patients with schizophrenia not sharing a single symptom), 
their treatment is more or less unimodal (antipsychotics) 
and the course of the disease is monotonous. In BD, however, 
the course is characterized by episodes of distinct clusters of 
symptoms while the resulting accumulated stress has a pro-
found adverse effect on neurocognition and general func-
tioning with the neurobiology of the patient to change under 
the pressure of what is called “allostatic load,” leading eventu-
ally to treatment resistance, disability, high comorbidity, and 
preterm mortality (Vieta et al., 2013).
When it comes to BD, things are quite different from other 
mental disorders. The reliability and validity of usual ap-
proaches are questionable because both the clinical picture and 
the treatment are complex and interrelated. Also, the course 
is not monotonous but, on the contrary, it manifests with un-
predictable switches with a complex and unique relationship 
between clinical symptoms and impairment. Another issue is 
the problematic interplay of the clinical picture with psycho-
metric scale scores when the longitudinal course of the disorder 
is complex, as in the case of BD. For example, the use of the 
MADRS scale to assess response to treatment with a tricyclic 
antidepressant could lead to erroneous conclusions in case this 
depressive BD patient becomes mixed or rapid cycling emerges. 
The MADRS will probably classify him as being a “responder,” 
but whether this is true is a matter of debate. Accepting sim-
plistic approaches cannot serve as a real solution.
The current study developed a definition of treatment resist-
ance in BD and an algorithm for its treatment. These were based 
on a thorough and deep search of the literature. During the last 
couple of decades, our knowledge concerning the treatment of 
BD has changed radically (Grande et al., 2016; Vieta et al., 2018), 
and a rather narrow therapeutic effect for most agents is ac-
cepted, so narrow that the very existence of the term “mood 
stabilizer” is under question. Further, the collapse of the “class 
effect” approach to BD treatment (Rosa et al., 2011) raises im-
portant questions as to which patients are truly resistant and 
which were simply treated in a suboptimal way.
The review of the literature suggested that there are some 
evidence-based options for the treatment of resistant acute 
mania but much fewer for the treatment of resistant depres-
sion, mixed states, and rapid cycling cases. Thus, the relative 
shortage of hard data (Poon et al., 2012) leaves the clinician in 
many cases with the heavy burden to decide on the basis of clin-
ical experience and wisdom. The current treatment guidelines 
on one hand rely on hard data; however, they provide a limited 
number of options for the treatment of a variety of cases, and 
without the ability to tailor treatment to the clinical picture and 
the specific needs of the individual patient. Future specific and 
targeted research is essential and necessary to test possible 
treatment approaches for resistant patients of all kinds.
Most of the problems concerning the interplay of clinical 
features with definitions of response and resistance, especially 
for the maintenance phase, have been discussed elsewhere 
(Ghaemi et al., 2004; Fountoulakis, 2010; Vieta and Garriga, 2016; 
Fountoulakis et al., 2017b, 2017c, 2017d). Clinical wisdom is also 
of high importance in the planning of long-term treatment of 
BD patients. In this frame, the concept of “predominant polarity” 
and the “polarity index” of a given agent are of great importance 
since it guides the clinician to tailor treatment to the specific 
needs of the specific patient (Nivoli et al., 2011; Popovic et al., 
2012, 2013, 2014; Sentissi et al., 2019).
Better knowledge of the underlying neurobiological sub-
strate of treatment resistance in BD would be important, since 
the failure of physiological compensatory mechanisms over 
time, accompanied by neuroprogression and cross-sensitization 
of episode recurrence, trauma exposure, and substance use 
could constitute modifiable factors both in the prevention but 
also in the treatment of such cases (da Costa et al., 2016). So far, 
however, our knowledge does not permit a reliable prediction or 
assessment of resistant cases since no neurobiological or clin-
ical variables have proven reliable (Gonzalez-Isasi et al., 2012). 
However, the observation that psychoeducation is preferentially 
efficacious in patients with less than 7 episodes, while it has 
no effect in those with more than 14 episodes, provides us with 
a first clue of the stages and the timetable of the development 
of resistance (Colom et al., 2010; Bond and Anderson, 2015; van 
der Markt et al., 2019). On the other hand, while the stage of the 
progression of the disorder has been proposed as a factor that 
should be taken into consideration in the planning of treatment 
especially in resistant cases (Passos and Kapczinski, 2017), in es-
sence this might reflect a cyclical logic with treatment resist-
ance defining the stage and vice versa.
Statement of Interest
K.N.F.  has received grants and served as consultant, ad-
visor, or CME speaker for the following entities: AstraZeneca, 
Bristol-Myers Squibb, Eli Lilly, Ferrer, Gedeon Richter, Janssen, 
Lundbeck, Otsuka, Pfizer, the Pfizer Foundation, Sanofi-Aventis, 
Servier, Shire, and others. E.V. has received grants and served as 
consultant, advisor, or CME speaker for the following entities: 
AB-Biotics, Abbott, Allergan, Angelini, AstraZeneca, Bristol-
Myers Squibb, Dainippon Sumitomo Pharma, Ferrer, Forest 
Research Institute, Gedeon Richter, Glaxo-Smith-Kline, Janssen, 
Lilly, Lundbeck, Otsuka, Pfizer, Roche, SAGE, Sanofi-Aventis, 
Servier, Shire, Sunovion, Takeda, the Brain and Behaviour 
Foundation, the Generalitat de Catalunya (AGAUR and PERIS), 
the Spanish Ministry of Science, Innovation and Universities 
(AES and CIBERSAM), the Seventh European Framework 
Programme and Horizon 2020, and the Stanley Medical Research 
Institute. A.H.Y.  is employed by King’s College London; is 
Honorary Consultant SLaM (NHS UK); has paid lectures by and 
participated in advisory boards for all major pharmaceutical 
companies with drugs used in affective and related disorders; 
no shareholdings in pharmaceutical companies. He was lead in-
vestigator for Embolden Study (AZ), BCI Neuroplasticity study, 
and Aripiprazole Mania Study; investigator-initiated studies 
from AZ, Eli Lilly, Lundbeck, and Wyeth; and has received grant 
funding (past and present) from: NIHR-BRC (UK); NIMH (USA); 
CIHR (Canada); NARSAD (USA); Stanley Medical Research 
Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College 
of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); 
WEDC (Canada); CCS Depression Research Fund (Canada); 
MSFHR (Canada); NIHR (UK). H.G.  within the last 3  years re-
ceived honoraria or consultation fees from: Desitin, Gedeon-
Richter, Lundbeck, and Pfizer. L.Y. has been on speaker/advisory 
boards for, or has received research grants from Alkermes, 
Allergan, AstraZeneca, Bristol Myers Squibb, CANMAT, CIHR, 
Eli Lilly, Forest, GlaxoSmithKline, Intas, Janssen, the Michael 






/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
Copyedited by:  
Fountoulakis et al. | 245
Dainippon, Sunovion, and the Stanley Foundation. S.K.  within 
the last 3  years received grants/research support, consulting 
fees, and honoraria within the last 3 years from Angelini, AOP 
Orphan Pharmaceuticals AG, AstraZeneca, Eli Lilly, Janssen, 
KRKA-Pharma, Lundbeck, Neuraxpharm, Pfizer, Pierre Fabre, 
Schwabe, and Servier. H.J.M. received honoraria for lectures or for 
advisory activities or received grants by the following pharma-
ceutical companies: Lundbeck, Servier, Schwabe, and Bayer. He 
was president or on the executive board of the following or-
ganizations: CINP, ECNP, WFSBP, and EPA and chairman of the 
WPA-section on Pharmacopsychiatry. P.B. has received research 
grants from, honoraria for participation in advisory boards from, 
and/or gave presentations for: Allergan, Astra Zeneca, Bristol 
Myers Squibb, Canadian Institute for Health Research, Eli Lilly, 
Lundbeck, Janssen, Ontario Brain Institute, Meda-Valeant, Merck, 
Otsuka, Pierre Fabre Medicaments, Pfizer, Shire, Sunovion, and 
Takeda. M.T.  has been a consultant for AstraZeneca, Abbott, 
BMS, Lilly, GSK, J&J, Otsuka, Roche, Lundbeck, Elan, Allergan, 
Alkermes, Merck, Minerva, Neuroscience, Pamlab, Alexza, Forest, 
Teva, Sunovion, Gedeon Richter, and Wyeth. He was a full-time 
employee at Lilly (1997–2008). His spouse is a former employee 
at Lilly (1998–2013).
References
Aan Het Rot M, Zarate CA, Jr., Charney DS, Mathew SJ (2012) Keta-
mine for depression: where do we go from here? Biol Psych-
iatry 72:537–547.
Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R (2012) 
Rapid antidepressant effect of ketamine in the electroconvul-
sive therapy setting. J ECT 28:157–161.
Altshuler  LL, Keck  PE Jr, McElroy  SL, Suppes  T, Brown  ES, 
Denicoff K, Frye M, Gitlin M, Hwang S, Goodman R, Leverich G, 
Nolen W, Kupka R, Post R (1999) Gabapentin in the acute treat-
ment of refractory bipolar disorder. Bipolar Disord 1:61–65.
Altshuler  LL, Post  RM, Hellemann  G, Leverich  GS, Nolen  WA, 
Frye  MA, Keck  PE Jr, Kupka  RW, Grunze  H, McElroy  SL, 
Sugar CA, Suppes T (2009) Impact of antidepressant continu-
ation after acute positive or partial treatment response for 
bipolar depression: a blinded, randomized study. J Clin Psych-
iatry 70:450–457.
Amann BL, Mergl R, Vieta E, Born C, Hermisson I, Seemueller F, 
Dittmann S, Grunze H (2007) A 2-year, open-label pilot study 
of adjunctive chromium in patients with treatment-resistant 
rapid-cycling bipolar disorder. J Clin Psychopharmacol 
27:104–106.
American Psychiatric Association (2000) Diagnostic and Statis-
tical Manual of Mental Disorders 4th Edition, Text Revision, 
DSM-IV-TR. Washington, DC: American Psychiatric Publishing.
Amsterdam  JD, Lorenzo-Luaces  L, DeRubeis  RJ (2016a) Step-
wise loss of antidepressant effectiveness with repeated 
antidepressant trials in bipolar II depression. Bipolar Disord 
18:563–570.
Amsterdam  JD, Lorenzo-Luaces  L, Soeller  I, Li  SQ, Mao  JJ, 
DeRubeis  RJ (2016b) Short-term venlafaxine v.  lithium 
monotherapy for bipolar type II major depressive episodes: 
effectiveness and mood conversion rate. Br J Psychiatry 
208:359–365.
Anand A, Gunn AD, Barkay G, Karne HS, Nurnberger JI, Mathew SJ, 
Ghosh  S (2012) Early antidepressant effect of memantine 
during augmentation of lamotrigine inadequate response 
in bipolar depression: a double-blind, randomized, placebo-
controlled trial. Bipolar Disord 14:64–70.
Aronson  TA, Shukla  S, Hirschowitz  J (1989) Clonazepam treat-
ment of five lithium-refractory patients with bipolar disorder. 
Am J Psychiatry 146:77–80.
Baek JH, Ha K, Yatham LN, Chang JS, Ha TH, Jeon HJ, Hong KS, 
Chang SM, Ahn YM, Cho HS, Moon E, Cha B, Choi JE, Joo YH, 
Joo EJ, Lee SY, Park Y (2014) Pattern of pharmacotherapy by 
episode types for patients with bipolar disorders and its con-
cordance with treatment guidelines. J Clin Psychopharmacol 
34:577–587.
Ball  JR, Mitchell  PB, Corry  JC, Skillecorn  A, Smith  M, Malhi  GS 
(2006) A randomized controlled trial of cognitive therapy for 
bipolar disorder: focus on long-term change. J Clin Psychiatry 
67:277–286.
Barekatain  M, Jahangard  L, Haghighi  M, Ranjkesh  F (2008) 
Bifrontal versus bitemporal electroconvulsive therapy in se-
vere manic patients. J ECT 24:199–202.
Barton  BM, Gitlin  MJ (1987) Verapamil in treatment-resistant 
mania: an open trial. J Clin Psychopharmacol 7:101–103.
Bauer IE, Soares JC, Selek S, Meyer TD (2017) The Link between 
refractoriness and neuroprogression in treatment-resistant 
bipolar disorder. Mod Trends Pharmacopsychiatry 31:10–26.
Bauer  M (1994) Refractoriness induced by lithium discontinu-
ation despite adequate serum lithium levels. Am J Psychiatry 
151:1522.
Bauer M, Zaninelli R, Müller-Oerlinghausen B, Meister W (1999) 
Paroxetine and amitriptyline augmentation of lithium in the 
treatment of major depression: a double-blind study. J Clin 
Psychopharmacol 19:164–171.
Bauer M, Berghöfer A, Bschor T, Baumgartner A, Kiesslinger U, 
Hellweg R, Adli M, Baethge C, Müller-Oerlinghausen B (2002) 
Supraphysiological doses of L-thyroxine in the mainten-
ance treatment of prophylaxis-resistant affective disorders. 
Neuropsychopharmacology 27:620–628.
Bauer  M, Berman  S, Stamm  T, Plotkin  M, Adli  M, Pilhatsch  M, 
London  ED, Hellemann  GS, Whybrow  PC, Schlagenhauf  F 
(2016) Levothyroxine effects on depressive symptoms and 
limbic glucose metabolism in bipolar disorder: a randomized, 
placebo-controlled positron emission tomography study. Mol 
Psychiatry 21:229–236.
Bauer MS (1990) Rapid cycling bipolar affective disorder. Arch-
ives of General Psychiatry 47:435.
Bauer  MS, Whybrow  PC (1990) Rapid cycling bipolar affective 
disorder. II. Treatment of refractory rapid cycling with high-
dose levothyroxine: a preliminary study. Arch Gen Psychiatry 
47:435–440.
Behzadi AH, Omrani Z, Chalian M, Asadi S, Ghadiri M (2009) Folic 
acid efficacy as an alternative drug added to sodium val-
proate in the treatment of acute phase of mania in bipolar 
disorder: a double-blind randomized controlled trial. Acta 
Psychiatr Scand 120:441–445.
Benedetti A, Di Paolo A, Lastella M, Casamassima F, Candiracci C, 
Litta A, Ciofi L, Danesi R, Lattanzi L, Del Tacca M, Cassano GB 
(2010) Augmentation of clozapine with aripiprazole in severe 
psychotic bipolar and schizoaffective disorders: a pilot study. 
Clinical practice and epidemiology in mental health: CP & 
EMH 6:30–35.
Benedetti  F, Barbini  B, Fulgosi  MC, Colombo  C, Dallaspezia  S, 
Pontiggia A, Smeraldi E (2005) Combined total sleep depriv-
ation and light therapy in the treatment of drug-resistant 
bipolar depression: acute response and long-term remission 
rates. J Clin Psychiatry 66:1535–1540.
Berk  M, Copolov  DL, Dean  O, Lu  K, Jeavons  S, Schapkaitz  I, 






/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
246 | International Journal of Neuropsychopharmacology, 2020
pressive symptoms in bipolar disorder--a double-blind ran-
domized placebo-controlled trial. Biol Psychiatry 64:468–475.
Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi GS, Berk L, 
Conus  P, McGorry  PD (2011a) Does stage of illness impact 
treatment response in bipolar disorder? Empirical treatment 
data and their implication for the staging model and early 
intervention. Bipolar Disord 13:87–98.
Berk  M, Kapczinski  F, Andreazza  AC, Dean  OM, Giorlando  F, 
Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, 
Amminger P, McGorry P, Malhi GS (2011b) Pathways underlying 
neuroprogression in bipolar disorder: focus on inflammation, 
oxidative stress and neurotrophic factors. Neurosci Biobehav 
Rev 35:804–817.
Berk M, Turner A, Malhi GS, Ng CH, Cotton SM, Dodd S, Samuni 
Y, Tanious M, McAulay C, Dowling N, Sarris J, Owen L, 
Waterdrinker A, Smith D, Dean OM (2019a) A randomised 
controlled trial of a mitochondrial therapeutic target for bi-
polar depression: mitochondrial agents, N-acetylcysteine, 
and placebo. BMC Med 17:18.
Berk M, Turner A, Malhi GS, Ng CH, Cotton SM, Dodd S, Samuni 
Y, Tanious M, McAulay C, Dowling N, Sarris J, Owen L, 
Waterdrinker A, Smith D, Dean OM (2019b) Correction to: 
a randomised controlled trial of a mitochondrial thera-
peutic target for bipolar depression: mitochondrial agents, 
N-acetylcysteine, and placebo. BMC Med 17:35.
Bersudsky  Y, Applebaum  J, Gaiduk  Y, Sharony  L, Mishory  A, 
Podberezsky  A, Agam  G, Belmaker  RH (2010) Valnoctamide 
as a valproate substitute with low teratogenic potential in 
mania: a double-blind, controlled, add-on clinical trial. Bi-
polar Disord 12:376–382.
Berwaerts  J, Lane R, Nuamah  IF, Lim P, Remmerie B, Hough DW 
(2011) Paliperidone extended-release as adjunctive therapy to 
lithium or valproate in the treatment of acute mania: a ran-
domized, placebo-controlled study. J Affect Disord 129:252–260.
Bjørklund L, Horsdal HT, Mors O, Østergaard SD, Gasse C (2016) 
Trends in the psychopharmacological treatment of bi-
polar disorder: a nationwide register-based study. Acta 
Neuropsychiatr 28:75–84.
Bobo WV, Shelton RC (2010) Risperidone long-acting injectable 
(Risperdal Consta®) for maintenance treatment in patients 
with bipolar disorder. Expert Rev Neurother 10:1637–1658.
Bobo WV, Vande Voort JL, Croarkin PE, Leung JG, Tye SJ, Frye MA 
(2016) Ketamine for treatment-resistant unipolar and bipolar 
major depression: critical review and implications for clinical 
practice. Depress Anxiety 33:698–710.
Bocchetta A, Bernardi F, Burrai C, Pedditzi M, Del Zompo M (1993) 
A double-blind study of L-sulpiride versus amitriptyline 
in lithium-maintained bipolar depressives. Acta Psychiatr 
Scand 88:434–439.
Bond  K, Anderson  IM (2015) Psychoeducation for relapse pre-
vention in bipolar disorder: a systematic review of efficacy in 
randomized controlled trials. Bipolar Disord 17:349–362.
Bowden  CL, Calabrese  JR, McElroy  SL, Rhodes  LJ, Keck  PE Jr, 
Cookson  J, Anderson  J, Bolden-Watson  C, Ascher  J, Mona-
ghan E, Zhou J (1999) The efficacy of lamotrigine in rapid cyc-
ling and non-rapid cycling patients with bipolar disorder. Biol 
Psychiatry 45:953–958.
Brown  ES, Park  J, Marx  CE, Hynan  LS, Gardner  C, Davila  D, 
Nakamura A, Sunderajan P, Lo A, Holmes T (2014) A random-
ized, double-blind, placebo-controlled trial of pregnenolone 
for bipolar depression. Neuropsychopharmacology 39:2867–
2873.
Burdick KE, Braga RJ, Nnadi CU, Shaya Y, Stearns WH, Malhotra AK 
(2012) Placebo-controlled adjunctive trial of pramipexole in 
patients with bipolar disorder: targeting cognitive dysfunc-
tion. J Clin Psychiatry 73:103–112.
Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK (2014) Ketamine 
as the prototype glutamatergic antidepressant: pharmaco-
dynamic actions, and a systematic review and meta-analysis 
of efficacy. Ther Adv Psychopharmacol 4:75–99.
Calabrese  JR, Kimmel  SE, Woyshville  MJ, Rapport  DJ, Faust  CJ, 
Thompson  PA, Meltzer  HY (1996) Clozapine for treatment-
refractory mania. Am J Psychiatry 153:759–764.
Calabrese  JR, Bowden  CL, McElroy  SL, Cookson  J, Andersen  J, 
Keck  PE Jr, Rhodes  L, Bolden-Watson  C, Zhou  J, Ascher  JA 
(1999) Spectrum of activity of lamotrigine in treatment-
refractory bipolar disorder. Am J Psychiatry 156:1019–1023.
Calabrese  JR, Keck PE Jr, McElroy SL, Shelton MD (2001) A pilot 
study of topiramate as monotherapy in the treatment of 
acute mania. J Clin Psychopharmacol 21:340–342.
Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA 
(2010) Adjunctive armodafinil for major depressive episodes 
associated with bipolar I disorder: a randomized, multicenter, 
double-blind, placebo-controlled, proof-of-concept study. J 
Clin Psychiatry 71:1363–1370.
Calabrese JR, Frye MA, Yang R, Ketter TA; Armodafinil Treatment 
Trial Study Network (2014) Efficacy and safety of adjunctive 
armodafinil in adults with major depressive episodes asso-
ciated with bipolar I  disorder: a randomized, double-blind, 
placebo-controlled, multicenter trial. J Clin Psychiatry 
75:1054–1061.
Cardoso T de A, Campos Mondin T, Reyes AN, Zeni CP, Souza LD, 
da  Silva  RA, Jansen  K (2015) Biological rhythm and bipolar 
disorder: twelve-month follow-up of a randomized clinical 
trial. J Nerv Ment Dis 203:792–797.
Carlson BX, Ketter TA, Sun W, Timko K, McQuade RD, Sanchez R, 
Vester-Blokland  E, Marcus  R (2012) Aripiprazole in combin-
ation with lamotrigine for the long-term treatment of pa-
tients with bipolar I disorder (manic or mixed): a randomized, 
multicenter, double-blind study (CN138-392). Bipolar Disord 
14:41–53.
Chen  J, Muzina  DJ, Kemp  DE, Conroy  C, Chan  P, Serrano  MB, 
Ganocy SJ, Fang Y, Calabrese JR, Gao K (2011) Safety and efficacy 
of olanzapine monotherapy in treatment-resistant bipolar 
mania: a 12-week open-label study. Hum Psychopharmacol 
26:588–595.
Chen J, Lu Z, Zhang M, Zhang J, Ni X, Jiang X, Xu H, Heeramun-
Aubeeluck  A, Hu  Q, Jin  H, Davis  JM (2013) A randomized, 
4-week double-blind placebo control study on the efficacy 
of donepezil augmentation of lithium for treatment of acute 
mania. Neuropsychiatr Dis Treat 9:839–845.
Chengappa KN, Rathore D, Levine J, Atzert R, Solai L, Parepally H, 
Levin  H, Moffa  N, Delaney  J, Brar  JS (1999) Topiramate as 
add-on treatment for patients with bipolar mania. Bipolar 
Disord 1:42–53.
Chengappa  KN, Levine  J, Gershon  S, Mallinger  AG, Hardan  A, 
Vagnucci  A, Pollock  B, Luther  J, Buttenfield  J, Verfaille  S, 
Kupfer DJ (2000) Inositol as an add-on treatment for bipolar 
depression. Bipolar Disord 2:47–55.
Chiu CC, Huang SY, Chen CC, Su KP (2005) Omega-3 fatty acids 
are more beneficial in the depressive phase than in the manic 
phase in patients with bipolar I  disorder. J Clin Psychiatry 
66:1613–1614.
Ciapparelli  A, Dell’Osso  L, Pini  S, Chiavacci  MC, Fenzi  M, 
Cassano GB (2000) Clozapine for treatment-refractory schizo-
phrenia, schizoaffective disorder, and psychotic bipolar 







/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
Copyedited by:  
Fountoulakis et al. | 247
Ciapparelli  A, Dell’Osso  L, Bandettini  di  Poggio  A, Carmassi  C, 
Cecconi D, Fenzi M, Chiavacci MC, Bottai M, Ramacciotti CE, 
Cassano GB (2003) Clozapine in treatment-resistant patients 
with schizophrenia, schizoaffective disorder, or psychotic bi-
polar disorder: a naturalistic 48-month follow-up study. J Clin 
Psychiatry 64:451–458.
Ciappolino  V, Delvecchio  G, Agostoni  C, Mazzocchi  A, 
Altamura AC, Brambilla P (2017) The role of n-3 polyunsat-
urated fatty acids (n-3PUFAs) in affective disorders. J Affect 
Disord 224:32–47.
Cimpianu CL, Strube W, Falkai P, Palm U, Hasan A (2017) Vagus 
nerve stimulation in psychiatry: a systematic review of the 
available evidence. J Neural Transm (Vienna) 124:145–158.
Citrome  L (2010) Ziprasidone HCl capsules for the adjunctive 
maintenance treatment of bipolar disorder in adults. Expert 
Rev Neurother 10:1031–1037.
Cole AJ, Scott  J, Ferrier  IN, Eccleston D (1993) Patterns of treat-
ment resistance in bipolar affective disorder. Acta Psychiatr 
Scand 88:121–123.
Colom  F, Vieta  E, Martinez-Aran  A, Reinares  M, Goikolea  JM, 
Benabarre  A, Torrent  C, Comes  M, Corbella  B, Parramon  G, 
Corominas  J (2003) A randomized trial on the efficacy of 
group psychoeducation in the prophylaxis of recurrences 
in bipolar patients whose disease is in remission. Arch Gen 
Psychiatry 60:402–407.
Colom  F, Vieta  E, Sánchez-Moreno  J, Palomino-Otiniano  R, 
Reinares M, Goikolea JM, Benabarre A, Martínez-Arán A (2009) 
Group psychoeducation for stabilised bipolar disorders: 
5-year outcome of a randomised clinical trial. Br J Psychiatry 
194:260–265.
Colom  F, Reinares  M, Pacchiarotti  I, Popovic  D, Mazzarini  L, 
Martínez-Arán  A, Torrent  C, Rosa  A, Palomino-Otiniano  R, 
Franco C, Bonnin CM, Vieta E (2010) Has number of previous 
episodes any effect on response to group psychoeducation in 
bipolar patients? A 5-year follow-up post hoc analysis. Acta 
Neuropsychiatr 22:50–53.
Corp  SA, Gitlin  MJ, Altshuler  LL (2014) A review of the use of 
stimulants and stimulant alternatives in treating bipolar 
depression and major depressive disorder. J Clin Psychiatry 
75:1010–1018.
Costa  RT, Cheniaux  E, Rosaes  PA, Carvalho  MR, Freire  RC, 
Versiani M, Rangé BP, Nardi AE (2011) The effectiveness of cog-
nitive behavioral group therapy in treating bipolar disorder: 
a randomized controlled study. Braz J Psychiatry 33:144–149.
Coyle  CM, Laws  KR (2015) The use of ketamine as an anti-
depressant: a systematic review and meta-analysis. Hum 
Psychopharmacol 30:152–163.
da Costa SC, Passos  IC, Lowri C, Soares  JC, Kapczinski F (2016) 
Refractory bipolar disorder and neuroprogression. Prog 
Neuropsychopharmacol Biol Psychiatry 70:103–110.
Dauphinais DR, Rosenthal  JZ, Terman M, DiFebo HM, Tuggle C, 
Rosenthal NE (2012) Controlled trial of safety and efficacy of 
bright light therapy vs. negative air ions in patients with bi-
polar depression. Psychiatry Res 196:57–61.
de  Barros  Pellegrinelli  K, de  O  Costa  LF, Silval  KI, Dias  VV, 
Roso MC, Bandeira M, Colom F, Moreno RA (2013) Efficacy of 
psychoeducation on symptomatic and functional recovery in 
bipolar disorder. Acta Psychiatr Scand 127:153–158.
De  Beaurepaire  R (1992) Treatment of neuroleptic-resistant 
mania and schizoaffective disorders. Am J Psychiatry 
149:1614–1615.
Dell’Osso  B, Ketter  TA (2013) Assessing efficacy/effectiveness 
and safety/tolerability profiles of adjunctive pramipexole 
in bipolar depression: acute versus long-term data. Int Clin 
Psychopharmacol 28:297–304.
Dell’Osso B, Mundo E, D’Urso N, Pozzoli S, Buoli M, Ciabatti M, 
Rosanova M, Massimini M, Bellina V, Mariotti M, Altamura AC 
(2009) Augmentative repetitive navigated transcranial mag-
netic stimulation (rTMS) in drug-resistant bipolar depression. 
Bipolar Disord 11:76–81.
Denicoff KD, Smith-Jackson EE, Bryan AL, Ali SO, Post RM (1997) 
Valproate prophylaxis in a prospective clinical trial of refrac-
tory bipolar disorder. Am J Psychiatry 154:1456–1458.
Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, 
Khalife  S, Kammerer  WA, Quezado  Z, Luckenbaugh  DA, 
Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) 
A randomized add-on trial of an N-methyl-D-aspartate an-
tagonist in treatment-resistant bipolar depression. Arch Gen 
Psychiatry 67:793–802.
Dierckx  B, Heijnen  WT, van  den  Broek  WW, Birkenhäger  TK 
(2012) Efficacy of electroconvulsive therapy in bipolar versus 
unipolar major depression: a meta-analysis. Bipolar Disord 
14:146–150.
D’Urso  G, Dell’Osso  B, Rossi  R, Brunoni  AR, Bortolomasi  M, 
Ferrucci  R, Priori  A, de  Bartolomeis  A, Altamura  AC (2017) 
Clinical predictors of acute response to transcranial direct 
current stimulation (tDCS) in major depression. J Affect 
Disord 219:25–30.
Eden Evins A, Demopulos C, Nierenberg A, Culhane MA, Eisner L, 
Sachs G (2006) A double-blind, placebo-controlled trial of ad-
junctive donepezil in treatment-resistant mania. Bipolar 
Disord 8:75–80.
Erfurth A, Michael N, Stadtland C, Arolt V (2002) Bupropion as 
add-on strategy in difficult-to-treat bipolar depressive pa-
tients. Neuropsychobiology 45 (Suppl 1):33–36.
Esan  O, Osunbote  C, Oladele  O, Fakunle  S, Ehindero  C, 
Fountoulakis  KN (2017) Bipolar I  disorder in remission vs. 
schizophrenia in remission: is there a difference in burden? 
Compr Psychiatry 72:130–135.
Fan A, Berg A, Bresee C, Glassman LH, Rapaport MH (2012) Allo-
purinol augmentation in the outpatient treatment of bipolar 
mania: a pilot study. Bipolar Disord 14:206–210.
Fitzgerald  PB, Hoy  KE, Elliot  D, McQueen  S, Wambeek  LE, 
Daskalakis ZJ (2016) A negative double-blind controlled trial 
of sequential bilateral rTMS in the treatment of bipolar de-
pression. J Affect Disord 198:158–162.
Fond  G, Boyer  L (2014) Ketamine’s effectiveness in unipolar 
versus bipolar depression. Psychopharmacology (Berl) 
231:4417–4418.
Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, 
Micoulaud-Franchi JA, Richieri R, Courtet P, Abbar M, Roger M, 
Leboyer M, Boyer L (2014) Ketamine administration in depres-
sive disorders: a systematic review and meta-analysis. Psy-
chopharmacology (Berl) 231:3663–3676.
Fountoulakis KN (2010) An update of evidence-based treatment 
of bipolar depression: where do we stand? Curr Opin Psych-
iatry 23:19–24.
Fountoulakis KN (2012) Refractoriness in bipolar disorder: def-
initions and evidence-based treatment. CNS Neurosci Ther 
18:227–237.
Fountoulakis KN, Magiria S, Siamouli M, Panagiotidis P, 
Nimatoudis I, Iacovides A, Kaprinis GS (2007a) A seven- year 
follow-up of an extremely refractory bipolar I patient. CNS 
Spectr 12:733–734.
Fountoulakis KN, Siamouli M, Panagiotidis P, Magiria S, Kantartzis 






/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
248 | International Journal of Neuropsychopharmacology, 2020
episodes after antidepressant augmentation with modafinil. 
Prog Neuropsychopharmacol Biol Psychiatry 32:891–892.
Fountoulakis KN, Yatham L, Grunze H, Vieta E, Young A, Yatham 
L, Blier P, Kasper S, Moeller HJ (2017a) The International Col-
lege of Neuro-Psychopharmacology (CINP) treatment guide-
lines for bipolar disorder in adults (CINP-BD-2017), part 2: 
review, grading of the evidence, and a precise algorithm. Int J 
Neuropsychopharmacol 20:121–179.
Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier 
P, Kasper S, Moeller HJ (2017b) The International College of 
Neuro-Psychopharmacology (CINP) treatment guidelines for 
bipolar disorder in adults (CINP-BD-2017), part 3: the clinical 
guidelines. Int J Neuropsychopharmacol 20:180–195.
Fountoulakis KN, Vieta E, Young A, Yatham L, Grunze H, Blier 
P, Moeller HJ, Kasper S (2017c) The International College of 
Neuropsychopharmacology (CINP) Treatment Guidelines for 
Bipolar Disorder in Adults (CINP-BD-2017), part 4: unmet needs 
in the treatment of bipolar disorder and recommendations for 
future research. Int J Neuropsychopharmacol 20:196–205.
Fountoulakis KN, Young A, Yatham L, Grunze H, Vieta E, Blier 
P, Moeller HJ, Kasper S (2017d) The International College of 
Neuropsychopharmacology (CINP) Treatment Guidelines 
for Bipolar Disorder in Adults (CINP-BD-2017), part 1: back-
ground and methods of the development of guidelines. Int J 
Neuropsychopharmacol 20:98–120.
Fountoulakis KN, Kasper S, Andreassen O, Blier P, Okasha A, Se-
verus E, Versiani M, Tandon R, Moller HJ, Vieta E (2012) Efficacy 
of pharmacotherapy in bipolar disorder: a report by the WPA 
section on pharmacopsychiatry. Eur Arch Psychiatry Clin 
Neurosci 262(Suppl 1):1–48.
Fountoulakis KN, Gonda X, Baghai TC, Baldwin DS, Bauer M, Blier 
P, Gattaz W, Hasler G, Moller HJ, Tandon R, Vieta E, Kasper S 
(2015) Report of the WPA section of pharmacopsychiatry on 
the relationship of antiepileptic drugs with suicidality in epi-
lepsy. Int J Psychiatry Clin Pract 19:158–167.
Frangou  S, Lewis  M, McCrone  P (2006) Efficacy of ethyl-
eicosapentaenoic acid in bipolar depression: randomised 
double-blind placebo-controlled study. Br J Psychiatry 188:46–50.
Frangou  S, Lewis  M, Wollard  J, Simmons  A (2007) Preliminary 
in vivo evidence of increased N-acetyl-aspartate following 
eicosapentanoic acid treatment in patients with bipolar dis-
order. J Psychopharmacol 21:435–439.
Fries  GR, Pfaffenseller  B, Stertz  L, Paz  AV, Dargél  AA, Kunz  M, 
Kapczinski F (2012) Staging and neuroprogression in bipolar 
disorder. Curr Psychiatry Rep 14:667–675.
Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, 
Luckenbaugh  DA, Cora-Ocatelli  G, Leverich  GS, Post  RM 
(2000) A placebo-controlled study of lamotrigine and 
gabapentin monotherapy in refractory mood disorders. J Clin 
Psychopharmacol 20:607–614.
Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE Jr, Walden J, 
Leverich  GS, Altshuler  LL, Nakelsky  S, Hwang  S, Mintz  J, 
Post RM (2007) A placebo-controlled evaluation of adjunctive 
modafinil in the treatment of bipolar depression. Am J Psych-
iatry 164:1242–1249.
Gabriel A (2007) Adjunctive topiramate treatment in refractory 
obese bipolar patients: a descriptive open label study. Eat 
Weight Disord 12:48–53.
Gajwani  P (2009) Treatment-refractory bipolar disorder: clas-
sification to aid in clinical management. Expert Opin 
Pharmacother 10:1907–1915.
Galling  B, Garcia  MA, Osuchukwu  U, Hagi  K, Correll  CU (2015) 
Safety and tolerability of antipsychotic-mood stabilizer 
co-treatment in the management of acute bipolar disorder: 
results from a systematic review and exploratory meta-
analysis. Expert Opin Drug Saf 14:1181–1199.
Geddes  JR, Rendell  JM, Goodwin  GM (2002) BALANCE: a large 
simple trial of maintenance treatment for bipolar disorder. 
World Psychiatry 1:48–51.
Geddes JR, Gardiner A, Rendell J, Voysey M, Tunbridge E, Hinds C, 
Yu LM, Hainsworth J, Attenburrow MJ, Simon J, Goodwin GM, 
Harrison  PJ; CEQUEL Investigators and Collaborators (2016) 
Comparative evaluation of quetiapine plus lamotrigine com-
bination versus quetiapine monotherapy (and folic acid 
versus placebo) in bipolar depression (CEQUEL): a 2 × 2 fac-
torial randomised trial. Lancet Psychiatry 3:31–39.
Ghaemi  SN, Pardo  TB, Hsu  DJ (2004) Strategies for preventing 
the recurrence of bipolar disorder. J Clin Psychiatry 65 (Suppl 
10):16–23.
Ghanizadeh  A, OmraniSigaroodi  M, Javadpour  A, 
Dabbaghmanesh MH, Shafiee S (2014) Lovastatin as an adju-
vant to lithium for treating manic phase of bipolar disorder: 
a 4-week, randomized, double-blind, placebo-controlled clin-
ical trial. Depress Res Treat 2014:730505.
Gijsman  HJ, Geddes  JR, Rendell  JM, Nolen  WA, Goodwin  GM 
(2004) Antidepressants for bipolar depression: a system-
atic review of randomized, controlled trials. Am J Psychiatry 
161:1537–1547.
Gitlin M (2006) Treatment-resistant bipolar disorder. Mol Psych-
iatry 11:227–240.
Gitlin  MJ (2001) Treatment-resistant bipolar disorder. Bull 
Menninger Clin 65:26–40.
Goldberg  JF, Burdick  KE, Endick  CJ (2004) Preliminary random-
ized, double-blind, placebo-controlled trial of pramipexole 
added to mood stabilizers for treatment-resistant bipolar de-
pression. Am J Psychiatry 161:564–566.
Gomes  BC, Abreu  LN, Brietzke  E, Caetano  SC, Kleinman  A, 
Nery FG, Lafer B (2011) A randomized controlled trial of cogni-
tive behavioral group therapy for bipolar disorder. Psychother 
Psychosom 80:144–150.
González-Isasi A, Echeburúa E, Mosquera F, Ibáñez B, Aizpuru F, 
González-Pinto A (2010) Long-term efficacy of a psychological 
intervention program for patients with refractory bipolar dis-
order: a pilot study. Psychiatry Res 176:161–165.
González-Isasi A, Echeburúa E, Limiñana  JM, González-Pinto A 
(2012) Predictors of good outcome in patients with refrac-
tory bipolar disorder after a drug or a drug and cognitive-
behavioral treatment. Compr Psychiatry 53:224–229.
González  Isasi A, Echeburúa E, Limiñana  JM, González-Pinto A 
(2014) Psychoeducation and cognitive-behavioral therapy for 
patients with refractory bipolar disorder: a 5-year controlled 
clinical trial. Eur Psychiatry 29:134–141.
Grande  I, Berk  M, Birmaher  B, Vieta  E (2016) Bipolar disorder. 
Lancet 387:1561–1572.
Green  AI, Tohen  M, Patel  JK, Banov  M, DuRand  C, Berman  I, 
Chang H, Zarate C Jr, Posener J, Lee H, Dawson R, Richards C, 
Cole JO, Schatzberg AF (2000) Clozapine in the treatment of 
refractory psychotic mania. Am J Psychiatry 157:982–986.
Grosso  G, Pajak  A, Marventano  S, Castellano  S, Galvano  F, 
Bucolo C, Drago F, Caraci F (2014) Role of omega-3 fatty acids 
in the treatment of depressive disorders: a comprehen-
sive meta-analysis of randomized clinical trials. Plos One 
9:e96905.
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Azorin JM, 
Yatham  L, Mosolov  S, Möller  HJ, Kasper  S; Members of the 
WFSBP Task Force on Bipolar Affective Disorders Working on 
this topic (2018) The World Federation of Societies of Biological 






/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
Copyedited by:  
Fountoulakis et al. | 249
bipolar disorders: acute and long-term treatment of mixed 
states in bipolar disorder. World J Biol Psychiatry 19:2–58.
Harel  EV, Zangen  A, Roth  Y, Reti  I, Braw  Y, Levkovitz  Y (2011) 
H-coil repetitive transcranial magnetic stimulation for the 
treatment of bipolar depression: an add-on, safety and feasi-
bility study. World J Biol Psychiatry 12:119–126.
Harvey  AG, Soehner  AM, Kaplan  KA, Hein  K, Lee  J, Kanady  J, 
Li D, Rabe-Hesketh S, Ketter TA, Neylan TC, Buysse DJ (2015) 
Treating insomnia improves mood state, sleep, and func-
tioning in bipolar disorder: a pilot randomized controlled 
trial. J Consult Clin Psychol 83:564–577.
Hidalgo-Mazzei  D, et  al. (2019) Treatment-resistant and multi-
therapy-resistant criteria for bipolar depression: consensus 
definition. Br J Psychiatry 214:27–35.
Hiremani  RM, Thirthalli  J, Tharayil  BS, Gangadhar  BN (2008) 
Double-blind randomized controlled study comparing short-
term efficacy of bifrontal and bitemporal electroconvulsive 
therapy in acute mania. Bipolar Disord 10:701–707.
Holtzheimer PE, Kelley ME, Gross RE, Filkowski MM, Garlow SJ, 
Barrocas  A, Wint  D, Craighead  MC, Kozarsky  J, Chismar  R, 
Moreines  JL, Mewes  K, Posse  PR, Gutman  DA, Mayberg  HS 
(2012) Subcallosal cingulate deep brain stimulation for 
treatment-resistant unipolar and bipolar depression. Arch 
Gen Psychiatry 69:150–158.
Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, 
Schulz  KF; CONSORT Group (2008) CONSORT for reporting 
randomized controlled trials in journal and conference ab-
stracts: explanation and elaboration. Plos Med 5:e20.
Houston  JP, Ahl  J, Meyers  AL, Kaiser  CJ, Tohen  M, Baldessarini  RJ 
(2006) Reduced suicidal ideation in bipolar I  disorder mixed-
episode patients in a placebo-controlled trial of olanzapine com-
bined with lithium or divalproex. J Clin Psychiatry 67:1246–1252.
Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA 
(2009) Olanzapine-divalproex combination versus divalproex 
monotherapy in the treatment of bipolar mixed episodes: 
a double-blind, placebo-controlled study. J Clin Psychiatry 
70:1540–1547.
Hui  Poon  S, Sim  K, Baldessarini  RJ (2015) Pharmacological ap-
proaches for treatment-resistant bipolar disorder. Curr 
Neuropharmacol 13:592–604.
Investigators B, collaborators; Geddes  JR, Goodwin  GM, Ren-
dell  J, Azorin  JM, Cipriani A, Ostacher MJ, Morriss R, Alder N, 
Juszczak E (2010) Lithium plus valproate combination therapy 
versus monotherapy for relapse prevention in bipolar I disorder 
(BALANCE): a randomised open-label trial. Lancet 375:385–395.
Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA 
Jr (2015) A single infusion of ketamine improves depression 
scores in patients with anxious bipolar depression. Bipolar 
Disord 17:438–443.
Isasi  AG, Echeburúa  E, Limiñana  JM, González-Pinto  A (2010) 
How effective is a psychological intervention program for pa-
tients with refractory bipolar disorder? A  randomized con-
trolled trial. J Affect Disord 126:80–87.
Jahangard  L, Soroush  S, Haghighi  M, Ghaleiha  A, Bajoghli  H, 
Holsboer-Trachsler E, Brand S (2014) In a double-blind, ran-
domized and placebo-controlled trial, adjuvant allopurinol 
improved symptoms of mania in in-patients suffering from 
bipolar disorder. Eur Neuropsychopharmacol 24:1210–1221.
Juruena  MF, Ottoni  GL, Machado-Vieira  R, Carneiro  RM, 
Weingarthner  N, Marquardt  AR, Fleig  SS, Broilo  L, 
Busnello  EA (2009) Bipolar I  and II disorder residual symp-
toms: oxcarbazepine and carbamazepine as add-on treat-
ment to lithium in a double-blind, randomized trial. Prog 
Neuropsychopharmacol Biol Psychiatry 33:94–99.
Kagawa S, Mihara K, Nakamura A, Nemoto K, Suzuki T, Nagai G, 
Kondo T (2014) Relationship between plasma concentrations 
of lamotrigine and its early therapeutic effect of lamotrigine 
augmentation therapy in treatment-resistant depressive dis-
order. Ther Drug Monit 36:730–733.
Keck PE Jr, McElroy SL (2001) Definition, evaluation, and manage-
ment of treatment refractory mania. Psychopharmacol Bull 
35:130–148.
Keck PE Jr, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, 
Altshuler LL, Kupka R, Nolen WA, Leverich GS, Denicoff KD, 
Grunze H, Duan N, Post RM (2006) Double-blind, randomized, 
placebo-controlled trials of ethyl-eicosapentanoate in the 
treatment of bipolar depression and rapid cycling bipolar dis-
order. Biol Psychiatry 60:1020–1022.
Keller  MB, Lavori  PW, Kane  JM, Gelenberg  AJ, Rosenbaum  JF, 
Walzer EA, Baker LA (1992) Subsyndromal symptoms in bi-
polar disorder. A  comparison of standard and low serum 
levels of lithium. Arch Gen Psychiatry 49:371–376.
Kemp DE, Gao K, Fein EB, Chan PK, Conroy C, Obral S, Ganocy SJ, 
Calabrese  JR (2012) Lamotrigine as add-on treatment to 
lithium and divalproex: lessons learned from a double-blind, 
placebo-controlled trial in rapid-cycling bipolar disorder. Bi-
polar Disord 14:780–789.
Kessing  LV, Vradi  E, Andersen  PK (2016) Nationwide and 
population-based prescription patterns in bipolar disorder. 
Bipolar Disord 18:174–182.
Kessler  U, Schoeyen  HK, Andreassen  OA, Eide  GE, Hammar  Å, 
Malt UF, Oedegaard KJ, Morken G, Sundet K, Vaaler AE (2013) 
Neurocognitive profiles in treatment-resistant bipolar I and 
bipolar II disorder depression. BMC Psychiatry 13:105.
Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM (2006) 
Adjunctive aripiprazole in treatment-resistant bipolar de-
pression. Ann Clin Psychiatry 18:169–172.
Ketter  TA, Yang  R, Frye  MA (2015) Adjunctive armodafinil for 
major depressive episodes associated with bipolar I disorder. 
J Affect Disord 181:87–91.
Kimmel SE, Calabrese JR, Woyshville MJ, Meltzer HY (1994) Clo-
zapine in treatment-refractory mood disorders. J Clin Psych-
iatry 55(Suppl B):91–93.
Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, 
Correll  CU (2016) Single-dose infusion ketamine and non-
ketamine N-methyl-d-aspartate receptor antagonists for 
unipolar and bipolar depression: a meta-analysis of efficacy, 
safety and time trajectories. Psychol Med 46:1459–1472.
Koukopoulos A, Reginaldi D, Minnai G, Serra G, Pani L, Johnson FN 
(1995) The long term prophylaxis of affective disorders. Adv 
Biochem Psychopharmacol 49:127–147.
Koukopoulos  A, Reginaldi  D, Serra  G, Koukopoulos  A, Sani  G, 
Serra  G (2010) Antimanic and mood-stabilizing effect of 
memantine as an augmenting agent in treatment-resistant 
bipolar disorder. Bipolar Disord 12:348–349.
Kramlinger  KG, Post  RM (1989) Adding lithium carbonate to 
carbamazepine: antimanic efficacy in treatment-resistant 
mania. Acta Psychiatr Scand 79:378–385.
Kraus  C, Rabl  U, Vanicek  T, Carlberg  L, Popovic  A, Spies  M, 
Bartova  L, Gryglewski  G, Papageorgiou  K, Lanzenberger  R, 
Willeit M, Winkler D, Rybakowski JK, Kasper S (2017) Admin-
istration of ketamine for unipolar and bipolar depression. Int 
J Psychiatry Clin Pract 21:2–12.
Kusumakar V, Yatham LN (1997) An open study of lamotrigine 
in refractory bipolar depression. Psychiatry Res 72:145–
148.
Lally  N, Nugent  AC, Luckenbaugh  DA, Ameli  R, Roiser  JP, 






/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
250 | International Journal of Neuropsychopharmacology, 2020
neural correlates in treatment-resistant bipolar depression. 
Transl Psychiatry 4:e469.
Lattanzi  L, Dell’Osso  L, Cassano  P, Pini  S, Rucci  P, Houck  PR, 
Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB (2002) 
Pramipexole in treatment-resistant depression: a 16-week 
naturalistic study. Bipolar Disord 4:307–314.
Lee EE, Della Selva MP, Liu A, Himelhoch S (2015) Ketamine as 
a novel treatment for major depressive disorder and bipolar 
depression: a systematic review and quantitative meta-
analysis. Gen Hosp Psychiatry 37:178–184.
Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, Wang 
YS, Wang LJ, Lee IH, Wang TY, Yeh TL, Yang YK, Hong JS, Lu RB 
(2014a) The effects of add-on low-dose memantine on cytokine 
levels in bipolar II depression: a 12-week double-blind, ran-
domized controlled trial. J Clin Psychopharmacol 34:337–343.
Lee SY, Chen SL, Chang YH, Chen SH, Chu CH, Huang SY, Tzeng 
NS, Wang CL, Wang LJ, Lee IH, Yeh TL, Yang YK, Hong JS, Lu RB 
(2014b) Genotype variant associated with add-on memantine 
in bipolar II disorder. Int J Neuropsychopharmacol 17:189–197.
Li XB, Tang YL, Wang CY, de Leon J (2015) Clozapine for treatment-
resistant bipolar disorder: a systematic review. Bipolar Disord 
17:235–247.
Liberati  A, Altman  DG, Tetzlaff  J, Mulrow  C, Gøtzsche  PC, 
Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) 
The PRISMA statement for reporting systematic reviews and 
meta-analyses of studies that evaluate healthcare interven-
tions: explanation and elaboration. Bmj 339:b2700.
Lipsman  N, McIntyre  RS, Giacobbe  P, Torres  C, Kennedy  SH, 
Lozano AM (2010) Neurosurgical treatment of bipolar depres-
sion: defining treatment resistance and identifying surgical 
targets. Bipolar Disord 12:691–701.
Liu B, Zhang Y, Fang H, Liu J, Liu T, Li L (2017) Efficacy and safety 
of long-term antidepressant treatment for bipolar disorders 
- A  meta-analysis of randomized controlled trials. J Affect 
Disord 223:41–48.
Lobban F, Taylor L, Chandler C, Tyler E, Kinderman P, Kolamunnage-
Dona R, Gamble C, Peters S, Pontin E, Sellwood W, Morriss RK 
(2010) Enhanced relapse prevention for bipolar disorder by 
community mental health teams: cluster feasibility random-
ised trial. Br J Psychiatry 196:59–63.
Loebel  A, Cucchiaro  J, Silva  R, Kroger  H, Sarma  K, Xu  J, Cala-
brese JR (2014) Lurasidone as adjunctive therapy with lithium 
or valproate for the treatment of bipolar I depression: a ran-
domized, double-blind, placebo-controlled study. Am J Psych-
iatry 171:169–177.
Loo C, Katalinic N, Mitchell PB, Greenberg B (2011) Physical treat-
ments for bipolar disorder: a review of electroconvulsive 
therapy, stereotactic surgery and other brain stimulation 
techniques. J Affect Disord 132:1–13.
van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, 
de Keyzer HJ, Notten PJ, Luteijn ML, Timmermans MA, Vieta E, 
Nolen WA; LamLit Study Group (2009) Efficacy and safety of 
lamotrigine as add-on treatment to lithium in bipolar de-
pression: a multicenter, double-blind, placebo-controlled 
trial. J Clin Psychiatry 70:223–231.
van der Loos ML, Mulder P, Hartong EG, Blom MB, Vergouwen AC, 
van  Noorden  MS, Timmermans  MA, Vieta  E, Nolen  WA; 
LamLit Study Group (2010) Efficacy and safety of two treat-
ment algorithms in bipolar depression consisting of a com-
bination of lithium, lamotrigine or placebo and paroxetine. 
Acta Psychiatr Scand 122:246–254.
van der Loos ML, Mulder P, Hartong EG, Blom MB, Vergouwen AC, 
van Noorden MS, Timmermans MA, Vieta E, Nolen WA; LamLit 
Study Group (2011) Long-term outcome of bipolar depressed 
patients receiving lamotrigine as add-on to lithium with the 
possibility of the addition of paroxetine in nonresponders: a 
randomized, placebo-controlled trial with a novel design. Bi-
polar Disord 13:111–117.
Lykouras L, Hatzimanolis J (2004) Adjunctive topiramate in the 
maintenance treatment of bipolar disorders: an open-label 
study. Curr Med Res Opin 20:843–847.
Macfadden  W, Alphs  L, Haskins  JT, Turner  N, Turkoz  I, Bossie  C, 
Kujawa  M, Mahmoud  R (2009) A randomized, double-blind, 
placebo-controlled study of maintenance treatment with ad-
junctive risperidone long-acting therapy in patients with bipolar 
I disorder who relapse frequently. Bipolar Disord 11:827–839.
Machado-Vieira  R, Soares  JC, Lara  DR, Luckenbaugh  DA, 
Busnello  JV, Marca  G, Cunha  A, Souza  DO, Zarate  CA Jr, 
Kapczinski  F (2008) A double-blind, randomized, placebo-
controlled 4-week study on the efficacy and safety of the 
purinergic agents allopurinol and dipyridamole adjunctive to 
lithium in acute bipolar mania. J Clin Psychiatry 69:1237–1245.
Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, 
Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk 
M (2011a) N-acetylcysteine for major depressive episodes in 
bipolar disorder. Braz J Psychiatry 33:374–378.
Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, 
Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, 
Berk M (2011b) N-acetyl cysteine add-on treatment for bi-
polar II disorder: a subgroup analysis of a randomized 
placebocontrolled trial. J Affect Disord 129:317–320.
Magalhães  PV, Dean  OM, Bush  AI, Copolov  DL, Malhi  GS, 
Kohlmann  K, Jeavons  S, Schapkaitz  I, Anderson-Hunt  M, 
Berk M (2013) A preliminary investigation on the efficacy of 
N-acetyl cysteine for mania or hypomania. Aust N Z J Psych-
iatry 47:564–568.
Mahableshwarkar  AR, Calabrese  JR, Macek  TA, Budur  K, 
Adefuye  A, Dong  X, Hanson  E, Sachs  GS (2017) Efficacy and 
safety of sublingual ramelteon as an adjunctive therapy in the 
maintenance treatment of bipolar I disorder in adults: a phase 
3, randomized controlled trial. J Affect Disord 221:275–282.
Maj M, Pirozzi R, Magliano L (1995) Nonresponse to reinstituted 
lithium prophylaxis in previously responsive bipolar patients: 
prevalence and predictors. Am J Psychiatry 152:1810–1811.
Manning JS (2005) Burden of illness in bipolar depression. Prim 
Care Companion J Clin Psychiatry 7:259–267.
Marangell  LB, Suppes  T, Zboyan  HA, Prashad  SJ, Fischer  G, 
Snow  D, Sureddi  S, Allen  JC (2008) A 1-year pilot study of 
vagus nerve stimulation in treatment-resistant rapid-cycling 
bipolar disorder. J Clin Psychiatry 69:183–189.
Marcus  R, Khan  A, Rollin  L, Morris  B, Timko  K, Carson  W, 
Sanchez R (2011) Efficacy of aripiprazole adjunctive to lithium 
or valproate in the long-term treatment of patients with bi-
polar I disorder with an inadequate response to lithium or 
valproate monotherapy: a multicenter, double-blind, ran-
domized study. Bipolar Disord 13:133–144.
van der Markt A, Klumpers UM, Draisma S, Dols A, Nolen WA, 
Post  RM, Altshuler  LL, Frye  MA, Grunze  H, Keck  PE Jr, 
McElroy SL, Suppes T, Beekman AT, Kupka RW (2019) Testing a 
clinical staging model for bipolar disorder using longitudinal 
life chart data. Bipolar Disord 21:228–234.
McElroy  SL, Dessain  EC, Pope  HG Jr, Cole  JO, Keck  PE Jr, 
Frankenberg FR, Aizley HG, O’Brien S (1991) Clozapine in the 
treatment of psychotic mood disorders, schizoaffective dis-
order, and schizophrenia. J Clin Psychiatry 52:411–414.
McElroy SL, Soutullo CA, Keck PE Jr, Kmetz GF (1997) A pilot trial 
of adjunctive gabapentin in the treatment of bipolar disorder. 






/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
Copyedited by:  
Fountoulakis et al. | 251
McElroy SL, Frye M, Denicoff K, Altshuler L, Nolen W, Kupka R, 
Suppes T, Keck PE Jr, Leverich GS, Kmetz GF, Post RM (1998) 
Olanzapine in treatment-resistant bipolar disorder. J Affect 
Disord 49:119–122.
McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, 
Brown  ES, Nolen  WA, Kupka  RW, Rochussen  J, Leverich  GS, 
Post RM (2000) Open-label adjunctive topiramate in the treat-
ment of bipolar disorders. Biol Psychiatry 47:1025–1033.
McElroy SL, Winstanley EL, Martens B, Patel NC, Mori N, Moeller D, 
McCoy J, Keck PE Jr (2011) A randomized, placebo-controlled 
study of adjunctive ramelteon in ambulatory bipolar I  dis-
order with manic symptoms and sleep disturbance. Int Clin 
Psychopharmacol 26:48–53.
McElroy SL, Martens BE, Mori N, Blom TJ, Casuto LS, Hawkins JM, 
Keck PE Jr (2015) Adjunctive lisdexamfetamine in bipolar de-
pression: a preliminary randomized, placebo-controlled trial. 
Int Clin Psychopharmacol 30:6–13.
McGirr  A, Berlim  MT, Bond  DJ, Fleck  MP, Yatham  LN, Lam  RW 
(2015) A systematic review and meta-analysis of randomized, 
double-blind, placebo-controlled trials of ketamine in the 
rapid treatment of major depressive episodes. Psychol Med 
45:693–704.
McGirr A, Vöhringer PA, Ghaemi SN, Lam RW, Yatham LN (2016a) 
Safety and efficacy of adjunctive second-generation anti-
depressant therapy with a mood stabiliser or an atypical 
antipsychotic in acute bipolar depression: a systematic re-
view and meta-analysis of randomised placebo-controlled 
trials. Lancet Psychiatry 3:1138–1146.
McGirr  A, Karmani  S, Arsappa  R, Berlim  MT, Thirthalli  J, 
Muralidharan  K, Yatham  LN (2016b) Clinical efficacy and 
safety of repetitive transcranial magnetic stimulation in 
acute bipolar depression. World Psychiatry 15:85–86.
Medda  P, Perugi  G, Zanello  S, Ciuffa  M, Cassano  GB (2009) Re-
sponse to ECT in bipolar I, bipolar II and unipolar depression. 
J Affect Disord 118:55–59.
Medda  P, Perugi  G, Zanello  S, Ciuffa  M, Rizzato  S, Cassano  GB 
(2010) Comparative response to electroconvulsive therapy in 
medication-resistant bipolar I patients with depression and 
mixed state. J Ect 26:82–86.
Medda P, Toni C, Mariani MG, De Simone L, Mauri M, Perugi G 
(2015) Electroconvulsive therapy in 197 patients with a se-
vere, drug-resistant bipolar mixed state: treatment outcome 
and predictors of response. J Clin Psychiatry 76:1168–1173.
Mendlewicz  J, Massat  I, Linotte  S, Kasper  S, Konstantinidis  A, 
Lecrubier  Y, Montgomery  S, Serretti  A, Zohar  J, Souery  D; 
Group for the Study of Resistant Depression (GSRD) (2010) 
Identification of clinical factors associated with resistance to 
antidepressants in bipolar depression: results from an Euro-
pean Multicentre Study. Int Clin Psychopharmacol 25:297–301.
Merikangas  KR, Jin  R, He  JP, Kessler  RC, Lee  S, Sampson  NA, 
Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-
Mora  ME, Ono  Y, Posada-Villa  J, Sagar  R, Wells  JE, Zarkov  Z 
(2011) Prevalence and correlates of bipolar spectrum disorder 
in the world mental health survey initiative. Arch Gen Psych-
iatry 68:241–251.
Meyer TD, Hautzinger M (2012) Cognitive behaviour therapy and 
supportive therapy for bipolar disorders: relapse rates for treat-
ment period and 2-year follow-up. Psychol Med 42:1429–1439.
Miller  F, Tanenbaum  JH, Griffin  A, Ritvo  E (1991) Prediction of 
treatment response in bipolar, manic disorder. J Affect Disord 
21:75–77.
Mishory  A, Yaroslavsky  Y, Bersudsky  Y, Belmaker  RH (2000) 
Phenytoin as an antimanic anticonvulsant: a controlled 
study. Am J Psychiatry 157:463–465.
Mishory  A, Winokur  M, Bersudsky  Y (2003) Prophylactic effect 
of phenytoin in bipolar disorder: a controlled study. Bipolar 
Disord 5:464–467.
Miziou  S, Tsitsipa  E, Moysidou  S, Karavelas  V, Dimelis  D, 
Polyzoidou V, Fountoulakis KN (2015) Psychosocial treatment 
and interventions for bipolar disorder: a systematic review. 
Ann Gen Psychiatry 14:19.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group (2009) 
Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. Bmj 339:b2535.
Mukai  T, Kishi  T, Matsuda  Y, Iwata  N (2014) A meta-analysis 
of inositol for depression and anxiety disorders. Hum 
Psychopharmacol 29:55–63.
Mukherjee  S, Sackeim  HA, Lee  C (1988) Unilateral ECT in the 
treatment of manic episodes. Convuls Ther 4:74–80.
Murphy  BL, Stoll  AL, Harris  PQ, Ravichandran  C, Babb  SM, 
Carlezon WA Jr, Cohen BM (2012) Omega-3 fatty acid treat-
ment, with or without cytidine, fails to show therapeutic 
properties in bipolar disorder: a double-blind, randomized 
add-on clinical trial. J Clin Psychopharmacol 32:699–703.
Murphy  BL, Babb  SM, Ravichandran  C, Cohen  BM (2014) 
Oral SAMe in persistent treatment-refractory bipolar de-
pression: a double-blind, randomized clinical trial. J Clin 
Psychopharmacol 34:413–416.
Murray JB (1994) Lithium maintenance therapy for bipolar I pa-
tients: possible refractoriness to reinstitution after discon-
tinuation. Psychol Rep 74:355–361.
Murrough  JW, Perez  AM, Pillemer  S, Stern  J, Parides  MK, 
aan  het  Rot  M, Collins  KA, Mathew  SJ, Charney  DS, 
Iosifescu DV (2013) Rapid and longer-term antidepressant ef-
fects of repeated ketamine infusions in treatment-resistant 
major depression. Biol Psychiatry 74:250–256.
Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, 
Oakes  R, Pitts  CD (2001) Double-blind, placebo-controlled 
comparison of imipramine and paroxetine in the treatment 
of bipolar depression. Am J Psychiatry 158:906–912.
Nery  FG, Monkul  ES, Hatch  JP, Fonseca  M, Zunta-Soares  GB, 
Frey BN, Bowden CL, Soares JC (2008) Celecoxib as an adjunct 
in the treatment of depressive or mixed episodes of bipolar 
disorder: a double-blind, randomized, placebo-controlled 
study. Hum Psychopharmacol 23:87–94.
Newport DJ, Carpenter LL, McDonald WM, Potash  JB, Tohen M, 
Nemeroff CB; APA Council of Research Task Force on Novel 
Biomarkers and Treatments (2015) Ketamine and other 
NMDA antagonists: early clinical trials and possible mechan-
isms in depression. Am J Psychiatry 172:950–966.
Nierenberg  AA, Ostacher  MJ, Calabrese  JR, Ketter  TA, 
Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, 
Wisniewski SR, Sachs GS (2006) Treatment-resistant bipolar 
depression: a STEP-BD equipoise randomized effectiveness 
trial of antidepressant augmentation with lamotrigine, in-
ositol, or risperidone. Am J Psychiatry 163:210–216.
Nivoli AM, Pacchiarotti I, Rosa AR, Popovic D, Murru A, Valenti M, 
Bonnin  CM, Grande  I, Sanchez-Moreno  J, Vieta  E, Colom  F 
(2011) Gender differences in a cohort study of 604 bipolar 
patients: the role of predominant polarity. J Affect Disord 
133:443–449.
Norris ER, Burke K, Correll JR, Zemanek KJ, Lerman J, Primelo RA, 
Kaufmann MW (2013) A double-blind, randomized, placebo-
controlled trial of adjunctive ramelteon for the treatment of 
insomnia and mood stability in patients with euthymic bi-
polar disorder. J Affect Disord 144:141–147.
Nuñez  NA, Comai  S, Dumitrescu  E, Ghabrash  MF, Tabaka  J, 






/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
252 | International Journal of Neuropsychopharmacology, 2020
vantes  P, Booij  L, Gobbi  G (2018) Psychopathological and 
sociodemographic features in treatment-resistant unipolar 
depression versus bipolar depression: a comparative study. 
BMC Psychiatry 18:68.
Obrocea  GV, Dunn  RM, Frye  MA, Ketter  TA, Luckenbaugh  DA, 
Leverich GS, Speer AM, Osuch EA, Jajodia K, Post RM (2002) 
Clinical predictors of response to lamotrigine and gabapentin 
monotherapy in refractory affective disorders. Biol Psychiatry 
51:253–260.
Ogawa Y, Tajika A, Takeshima N, Hayasaka Y, Furukawa TA (2014) 
Mood stabilizers and antipsychotics for acute mania: a sys-
tematic review and meta-analysis of combination/augmen-
tation therapy versus monotherapy. CNS Drugs 28:989–1003.
Ostacher MJ (2014) When positive isn’t positive: the hopes and dis-
appointments of clinical trials. J Clin Psychiatry 75:e1186–e1187.
Pacchiarotti  I, Mazzarini  L, Colom  F, Sanchez-Moreno  J, Girardi  P, 
Kotzalidis GD, Vieta E (2009) Treatment-resistant bipolar depres-
sion: towards a new definition. Acta Psychiatr Scand 120:429–440.
Pae CU, Masand PS, Mandel FS, O’Gorman C (2012) Achieving and 
sustaining remission in bipolar I disorder with ziprasidone: 
a post hoc analysis of a 24-week, double-blind, placebo-
controlled study. Clin Drug Investig 32:747–754.
Pallanti  S, Grassi  G, Antonini  S, Quercioli  L, Salvadori  E, Hol-
lander E (2014) rTMS in resistant mixed states: an exploratory 
study. J Affect Disord 157:66–71.
Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G (2000) 
Gabapentin in bipolar disorder: a placebo-controlled trial 
of adjunctive therapy. Gabapentin Bipolar Disorder Study 
Group. Bipolar Disord 2:249–255.
Parikh  SV, LeBlanc  SR, Ovanessian  MM (2010) Advancing bi-
polar disorder: key lessons from the Systematic Treatment 
Enhancement Program for Bipolar Disorder (STEP-BD). Can J 
Psychiatry 55:136–143.
Parker GB, Graham RK (2017) Clinical characteristics associated 
with treatment-resistant bipolar disorder. J Nerv Ment Dis 
205:188–191.
Parsaik AK, Singh B, Khosh-Chashm D, Mascarenhas SS (2015) 
Efficacy of ketamine in bipolar depression: systematic review 
and meta-analysis. J Psychiatr Pract 21:427–435.
Passos IC, Kapczinski F (2017) Should bipolar disorder treatment 
be modified depending on staging? Expert Rev Neurother 
17:93–95.
Patkar  AA, Pae  CU, Vöhringer  PA, Mauer  S, Narasimhan  M, 
Dalley S, Loebel A, Masand PS, Ghaemi SN (2015) A 13-week, 
randomized double-blind, placebo-controlled, cross-over 
trial of ziprasidone in bipolar spectrum disorder. J Clin 
Psychopharmacol 35:319–323.
Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB (1993) 
Preliminary controlled trial of nimodipine in ultra-rapid cyc-
ling affective dysregulation. Psychiatry Res 49:257–272.
Pazzaglia  PJ, Post  RM, Ketter  TA, Callahan  AM, Marangell  LB, 
Frye  MA, George  MS, Kimbrell  TA, Leverich  GS, Cora-
Locatelli G, Luckenbaugh D (1998) Nimodipine monotherapy 
and carbamazepine augmentation in patients with refractory 
recurrent affective illness. J Clin Psychopharmacol 18:404–
413.
Perry  A, Tarrier  N, Morriss  R, McCarthy  E, Limb  K (1999) Ran-
domised controlled trial of efficacy of teaching patients with 
bipolar disorder to identify early symptoms of relapse and 
obtain treatment. Bmj 318:149–153.
Perugi G, Toni C, Ruffolo G, Sartini S, Simonini E, Akiskal H (1999) 
Clinical experience using adjunctive gabapentin in treatment-
resistant bipolar mixed states. Pharmacopsychiatry 32:136–141.
Perugi G, Toni C, Frare F, Ruffolo G, Moretti L, Torti C, Akiskal HS 
(2002) Effectiveness of adjunctive gabapentin in resistant bi-
polar disorder: is it due to anxious-alcohol abuse comorbidity? 
J Clin Psychopharmacol 22:584–591.
Perugi G, Medda P, Zanello S, Toni C, Cassano GB (2012) Episode 
length and mixed features as predictors of ECT nonresponse 
in patients with medication-resistant major depression. 
Brain Stimul 5:18–24.
Perugi G, Medda P, Toni C, Mariani MG, Socci C, Mauri M (2017) The 
role of electroconvulsive therapy (ECT) in bipolar disorder: ef-
fectiveness in 522 patients with bipolar depression, mixed-state, 
mania and catatonic features. Curr Neuropharmacol 15:359–371.
Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, 
Owoeye  O, Batten  LA, Blier  P (2019) Single, repeated, and 
maintenance ketamine infusions for treatment-resistant 
depression: a randomized controlled trial. Am J Psychiatry 
176:401–409.
Pilhatsch M, Wolf R, Winter C, Lewitzka U, Bauer M (2010) Com-
parison of paroxetine and amitriptyline as adjunct to lithium 
maintenance therapy in bipolar depression: a reanalysis of a 
randomized, double-blind study. J Affect Disord 126:453–457.
Poleszczyk  A, Rakowicz  M, Parnowski  T, Antczak  J, Święcicki  Ł 
(2018) Are there clinical and neurophysiologic predictive 
factors for a positive response to HF-rTMS in patients with 
treatment-resistant depression? Psychiatry Res 264:175–181.
Poon SH, Sim K, Sum MY, Kuswanto CN, Baldessarini RJ (2012) 
Evidence-based options for treatment-resistant adult bipolar 
disorder patients. Bipolar Disord 14:573–584.
Pope  HG (1991) Valproatereatment of Acute Mania. Arch Gen 
Psychiatry 48:62.
Pope  HG Jr, McElroy  SL, Keck  PE Jr, Hudson  JI (1991) Valproate 
in the treatment of acute mania. A placebo-controlled study. 
Arch Gen Psychiatry 48:62–68.
Popovic  D, Reinares  M, Goikolea  JM, Bonnin  CM, Gonzalez-
Pinto  A, Vieta  E (2012) Polarity index of pharmacological 
agents used for maintenance treatment of bipolar disorder. 
Eur Neuropsychopharmacol 22:339–346.
Popovic D, Reinares M, Scott J, Nivoli A, Murru A, Pacchiarotti I, 
Vieta E, Colom F (2013) Polarity index of psychological inter-
ventions in maintenance treatment of bipolar disorder. 
Psychother Psychosom 82:292–298.
Popovic  D, Torrent  C, Goikolea  JM, Cruz  N, Sánchez-Moreno  J, 
González-Pinto A, Vieta E (2014) Clinical implications of pre-
dominant polarity and the polarity index in bipolar disorder: 
a naturalistic study. Acta Psychiatr Scand 129:366–374.
Post  RM (2012) Acquired lithium resistance revisited: 
discontinuation-induced refractoriness versus tolerance. J 
Affect Disord 140:6–13.
Post RM, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, 
Leverich GS, Kupka R, Nolen WA, Luckenbaugh DA, Walden J, 
Grunze  H (2005) Preliminary observations on the effective-
ness of levetiracetam in the open adjunctive treatment of re-
fractory bipolar disorder. J Clin Psychiatry 66:370–374.
Post  RM, Altshuler  LL, Frye  MA, Suppes  T, Rush  AJ, Keck  PE Jr, 
McElroy  SL, Denicoff  KD, Leverich  GS, Kupka  R, Nolen  WA 
(2001) Rate of switch in bipolar patients prospectively treated 
with second-generation antidepressants as augmentation to 
mood stabilizers. Bipolar Disord 3:259–265.
Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, 
Suppes T, McElroy S, Keck PE, Denicoff KD, Grunze H, Walden J, 
Kitchen  CM, Mintz  J (2006) Mood switch in bipolar depres-
sion: comparison of adjunctive venlafaxine, bupropion and 






/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
Copyedited by:  
Fountoulakis et al. | 253
Post  RM, Leverich  G (2008) Loss of previous responsiveness to 
lithium following its discontinuation and subsequent epi-
sode recurrence. In: Treatment of Bipolar Illness: A Casebook 
for Clinicians and Patients (Post RM, Leverich G, eds), pp 123–
130. New York: WW Norton, Inc.
Post RM, Leverich GS, Altshuler L, Mikalauskas K (1992) Lithium-
discontinuation-induced refractoriness: preliminary obser-
vations. Am J Psychiatry 149:1727–1729.
Post  RM, Leverich  GS, Pazzaglia  P, Mikalauskas  K, Denicoff  K 
(1993) Lithium tolerance and discontinuation as pathways to 
refractoriness. In: Lithium in Medicine and Biology (Birch N, 
Padgham C, Hughes M, eds), pp 71–84. Lancashire, UK: Marius 
Press.
Potter WZ, Murphy DL, Wehr TA, Linnoila M, Goodwin FK (1982) 
Clorgyline. A  new treatment for patients with refractory 
rapid-cycling disorder. Arch Gen Psychiatry 39:505–510.
Quante  A, Zeugmann  S, Luborzewski  A, Schommer  N, 
Langosch  J, Born C, Anghelescu  I, Wolf  J (2010) Aripiprazole 
as adjunct to a mood stabilizer and citalopram in bipolar de-
pression: a randomized placebo-controlled pilot study. Hum 
Psychopharmacol 25:126–132.
Quiroz  JA, Yatham  LN, Palumbo  JM, Karcher  K, Kushner  S, 
Kusumakar  V (2010) Risperidone long-acting injectable 
monotherapy in the maintenance treatment of bipolar I dis-
order. Biol Psychiatry 68:156–162.
Regenold WT, Noorani RJ, Piez D, Patel P (2015) Nonconvulsive 
electrotherapy for treatment resistant unipolar and bipolar 
major depressive disorder: a proof-of-concept trial. Brain 
Stimul 8:855–861.
Reinares  M, Colom  F, Rosa  AR, Bonnín  CM, Franco  C, Solé  B, 
Kapczinski F, Vieta E (2010) The impact of staging bipolar dis-
order on treatment outcome of family psychoeducation. J Af-
fect Disord 123:81–86.
Reinares M, Sánchez-Moreno J, Fountoulakis KN (2014) Psycho-
social interventions in bipolar disorder: what, for whom, and 
when. J Affect Disord 156:46–55.
Rendell  JM, Juszczak  E, Hainsworth  J, Gucht  EV, Healey  C, 
Morriss  R, Ferrier  N, Young  AH, Young  H, Goodwin  GM, 
Geddes  JR (2004) Developing the BALANCE trail–the role of 
the pilot study and start-up phase. Bipolar Disord 6:26–31.
Romeo B, Choucha W, Fossati P, Rotge JY (2015) Meta-analysis of 
short- and mid-term efficacy of ketamine in unipolar and bi-
polar depression. Psychiatry Res 230:682–688.
Rosa AR, Fountoulakis K, Siamouli M, Gonda X, Vieta E (2011) Is 
anticonvulsant treatment of mania a class effect? Data from 
randomized clinical trials. CNS Neurosci Ther 17:167–177.
Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, 
Mansur  RB, Brietzke  E, Goldstein  BI, McIntyre  RS (2016) 
Anti-inflammatory agents in the treatment of bipolar depres-
sion: a systematic review and meta-analysis. Bipolar Disord 
18:89–101.
Roy  Chengappa  KN, Schwarzman  LK, Hulihan  JF, Xiang  J, 
Rosenthal NR; Clinical Affairs Product Support Study-168 In-
vestigators (2006) Adjunctive topiramate therapy in patients 
receiving a mood stabilizer for bipolar I disorder: a random-
ized, placebo-controlled trial. J Clin Psychiatry 67:1698–1706.
Rybakowski  JK, Permoda-Osip  A, Skibinska  M, Adamski  R, 
Bartkowska-Sniatkowska  A (2013) Single ketamine infu-
sion in bipolar depression resistant to antidepressants: are 
neurotrophins involved? Hum Psychopharmacol 28:87–90.
Rybakowski  JK, Permoda-Osip  A, Bartkowska-Sniatkowska  A 
(2017) Ketamine augmentation rapidly improves depression 
scores in inpatients with treatment-resistant bipolar depres-
sion. Int J Psychiatry Clin Pract 21:99–103.
Sachs  G, Chengappa  KN, Suppes  T, Mullen  JA, Brecher  M, 
Devine  NA, Sweitzer  DE (2004) Quetiapine with lithium or 
divalproex for the treatment of bipolar mania: a random-
ized, double-blind, placebo-controlled study. Bipolar Disord 
6:213–223.
Sachs  GS (1996) Treatment-resistant bipolar depression. 
Psychiatr Clin North Am 19:215–236.
Sachs  GS, Lafer  B, Stoll  AL, Banov  M, Thibault  AB, Tohen  M, 
Rosenbaum JF (1994) A double-blind trial of bupropion versus 
desipramine for bipolar depression. J Clin Psychiatry 55:391–
393.
Sachs  GS, Ice  KS, Chappell  PB, Schwartz  JH, Gurtovaya  O, 
Vanderburg  DG, Kasuba  B (2011) Efficacy and safety of ad-
junctive oral ziprasidone for acute treatment of depression in 
patients with bipolar I disorder: a randomized, double-blind, 
placebo-controlled trial. J Clin Psychiatry 72:1413–1422.
Sachs  GS, Vanderburg  DG, Karayal  ON, Kolluri  S, Bachinsky  M, 
Cavus I (2012a) Adjunctive oral ziprasidone in patients with 
acute mania treated with lithium or divalproex, part 1: re-
sults of a randomized, double-blind, placebo-controlled trial. 
J Clin Psychiatry 73:1412–1419.
Sachs  GS, Vanderburg  DG, Edman  S, Karayal  ON, Kolluri  S, 
Bachinsky M, Cavus I (2012b) Adjunctive oral ziprasidone in 
patients with acute mania treated with lithium or divalproex, 
part 2: influence of protocol-specific eligibility criteria on 
signal detection. J Clin Psychiatry 73:1420–1425.
Sajatovic M, DiGiovanni SK, Bastani B, Hattab H, Ramirez LF (1996) 
Risperidone therapy in treatment refractory acute bipolar and 
schizoaffective mania. Psychopharmacol Bull 32:55–61.
Sajatovic M, Subramoniam M, Fuller MA (2006) Risperidone in 
the treatment of bipolar mania. Neuropsychiatr Dis Treat 
2:127–138.
Saligan  LN, Luckenbaugh  DA, Slonena  EE, Machado-Vieira  R, 
Zarate CA Jr (2016) An assessment of the anti-fatigue effects 
of ketamine from a double-blind, placebo-controlled, cross-
over study in bipolar disorder. J Affect Disord 194:115–119.
Sampaio-Junior  B, Tortella  G, Borrione  L, Moffa  AH, Machado-
Vieira R, Cretaz E, Fernandes da Silva A, Fraguas R, Aparício LV, 
Klein I, Lafer B, Goerigk S, Benseñor IM, Lotufo PA, Gattaz WF, 
Brunoni AR (2018) Efficacy and safety of transcranial direct 
current stimulation as an add-on treatment for bipolar de-
pression: a randomized clinical trial. JAMA Psychiatry 75:158–
166.
Sandu  AL, Artiges  E, Galinowski  A, Gallarda  T, Bellivier  F, 
Lemaitre H, Granger B, Ringuenet D, Tzavara ET, Martinot JL, 
Paillère Martinot ML (2017) Amygdala and regional volumes 
in treatment-resistant versus nontreatment-resistant de-
pression patients. Depress Anxiety 34:1065–1071.
Sanford  M, Dhillon  S (2015) Lurasidone: a review of its use in 
adult patients with bipolar I depression. CNS Drugs 29:253–
263.
Saricicek  A, Maloney  K, Muralidharan  A, Ruf  B, Blumberg  HP, 
Sanacora  G, Lorberg  B, Pittman  B, Bhagwagar  Z (2011) 
Levetiracetam in the management of bipolar depression: a 
randomized, double-blind, placebo-controlled trial. J Clin 
Psychiatry 72:744–750.
Sarris J, Mischoulon D, Schweitzer I (2012) Omega-3 for bipolar 
disorder: meta-analyses of use in mania and bipolar depres-
sion. J Clin Psychiatry 73:81–86.
Schaff MR, Fawcett J, Zajecka JM (1993) Divalproex sodium in the 
treatment of refractory affective disorders. J Clin Psychiatry 
54:380–384.
Schaffer  A, Levitt  AJ, Joffe  RT (2000) Mexiletine in treatment-






/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
254 | International Journal of Neuropsychopharmacology, 2020
Schaffer  A, Zuker  P, Levitt  A (2006) Randomized, double-blind 
pilot trial comparing lamotrigine versus citalopram for the 
treatment of bipolar depression. J Affect Disord 96:95–99.
Schaffer C, Schaffer L, Howe J (2017) Treatment-resistant bipolar 
disorder. Psychiatric Times 34:33–35.
Schaffer  CB, Schaffer  LC (1999) Open maintenance treatment 
of bipolar disorder spectrum patients who responded to 
gabapentin augmentation in the acute phase of treatment. J 
Affect Disord 55:237–240.
Schaffer LC, Schaffer CB, Caretto J (1999) The use of primidone in 
the treatment of refractory bipolar disorder. Ann Clin Psych-
iatry 11:61–66.
Schaffer  LC, Schaffer  CB, Miller  AR, Manley  JL, Piekut  JA, 
Nordahl  TE (2013) An open trial of pregabalin as an acute 
and maintenance adjunctive treatment for outpatients with 
treatment resistant bipolar disorder. J Affect Disord 147:407–
410.
Scherk  H, Pajonk  FG, Leucht  S (2007) Second-generation anti-
psychotic agents in the treatment of acute mania: a sys-
tematic review and meta-analysis of randomized controlled 
trials. Arch Gen Psychiatry 64:442–455.
Schoeyen  HK, Kessler  U, Andreassen  OA, Auestad  BH, 
Bergsholm P, Malt UF, Morken G, Oedegaard KJ, Vaaler A (2015) 
Treatment-resistant bipolar depression: a randomized con-
trolled trial of electroconvulsive therapy versus algorithm-
based pharmacological treatment. Am J Psychiatry 172:41–51.
Scott  J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, 
Abbott  R, Hayhurst  H (2006) Cognitive-behavioural therapy 
for severe and recurrent bipolar disorders: randomised con-
trolled trial. Br J Psychiatry 188:313–320.
Sentissi  O, Popovic  D, Moeglin  C, Stukalin  YB, Mosheva  M, 
Vieta E, Serretti A, Souery D (2019) Predominant polarity in 
bipolar disorder patients: the COPE bipolar sample. J Affect 
Disord 250:43–50.
Shelton RC, Stahl SM (2004) Risperidone and paroxetine given 
singly and in combination for bipolar depression. J Clin 
Psychiatry 65:1715–1719.
Sidor MM, Macqueen GM (2011) Antidepressants for the acute 
treatment of bipolar depression: a systematic review and 
meta-analysis. J Clin Psychiatry 72:156–167.
Sienaert P, Lambrichts L, Dols A, De Fruyt J (2013) Evidence-based 
treatment strategies for treatment-resistant bipolar depres-
sion: a systematic review. Bipolar Disord 15:61–69.
Sikdar S, Kulhara P, Avasthi A, Singh H (1994) Combined chlor-
promazine and electroconvulsive therapy in mania. Br J 
Psychiatry 164:806–810.
Silverstone  PH, Birkett  L (2000) Diltiazem as augmentation 
therapy in patients with treatment-resistant bipolar dis-
order: a retrospective study. J Psychiatry Neurosci 25:276–280.
Sit DK, McGowan J, Wiltrout C, Diler RS, Dills JJ, Luther J, Yang A, 
Ciolino JD, Seltman H, Wisniewski SR, Terman M, Wisner KL 
(2018) Adjunctive bright light therapy for bipolar depression: 
a randomized double-blind placebo-controlled trial. Am J 
Psychiatry 175:131–139.
Smith  LA, Cornelius  V, Warnock  A, Tacchi  MJ, Taylor  D (2007) 
Acute bipolar mania: a systematic review and meta-analysis 
of co-therapy vs. monotherapy. Acta Psychiatr Scand 115:12–
20.
Stamm  TJ, Lewitzka  U, Sauer  C, Pilhatsch  M, Smolka  MN, 
Koeberle  U, Adli  M, Ricken  R, Scherk  H, Frye  MA, Juckel  G, 
Assion  HJ, Gitlin  M, Whybrow  PC, Bauer  M (2014) 
Supraphysiologic doses of levothyroxine as adjunctive 
therapy in bipolar depression: a randomized, double-blind, 
placebo-controlled study. J Clin Psychiatry 75:162–168.
Stoll  AL, Severus  WE, Freeman  MP, Rueter  S, Zboyan  HA, Dia-
mond E, Cress KK, Marangell LB (1999) Omega 3 fatty acids 
in bipolar disorder: a preliminary double-blind, placebo-
controlled trial. Arch Gen Psychiatry 56:407–412.
Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ (1999) 
Clinical outcome in a randomized 1-year trial of clozapine 
versus treatment as usual for patients with treatment-
resistant illness and a history of mania. Am J Psychiatry 
156:1164–1169.
Suppes  T, Chisholm  KA, Dhavale  D, Frye  MA, Altshuler  LL, 
McElroy  SL, Keck  PE, Nolen  WA, Kupka  R, Denicoff  KD, 
Leverich GS, Rush AJ, Post RM (2002) Tiagabine in treatment 
refractory bipolar disorder: a clinical case series. Bipolar 
Disord 4:283–289.
Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ (2003) 
Clinical outcome in a randomized 1-year trial of clozapine 
versus treatment as usual for patients with treatment-
resistant illness and a history of mania. Focus 1:37–43.
Suppes T, Ozcan ME, Carmody T (2004) Response to clozapine 
of rapid cycling versus non-cycling patients with a history of 
mania. Bipolar Disord 6:329–332.
Suppes T, Calabrese JR, Silva R, Kroger H, Cucchiaro J, Pikalov A, 
Loebel A (2013) Lurasidone adjunctive therapy with lithium 
or valproate for the treatment of bipolar I depression: a ran-
domized, double-blind, placebo-controlled study (PREVAIL 3). 
Neuropsychopharmacology 38:S533–S534.
Suppes  T, Kroger  H, Pikalov  A, Loebel  A (2016) Lurasidone ad-
junctive with lithium or valproate for bipolar depression: 
a placebo-controlled trial utilizing prospective and retro-
spective enrolment cohorts. J Psychiatr Res 78:86–93.
Swann  AC, Bowden  CL, Calabrese  JR, Dilsaver  SC, Morris  DD 
(1999) Differential effect of number of previous episodes of 
affective disorder on response to lithium or divalproex in 
acute mania. Am J Psychiatry 156:1264–1266.
Sylvia  LG, Peters  AT, Deckersbach  T, Nierenberg  AA (2013) 
Nutrient-based therapies for bipolar disorder: a systematic 
review. Psychother Psychosom 82:10–19.
Szegedi  A, Calabrese  JR, Stet  L, Mackle  M, Zhao  J, Panagides  J; 
Apollo Study Group (2012) Asenapine as adjunctive treat-
ment for acute mania associated with bipolar disorder: re-
sults of a 12-week core study and 40-week extension. J Clin 
Psychopharmacol 32:46–55.
Szmulewicz  AG, Angriman  F, Samamé  C, Ferraris  A, Vigo  D, 
Strejilevich SA (2017) Dopaminergic agents in the treatment 
of bipolar depression: a systematic review and meta-analysis. 
Acta Psychiatr Scand 135:527–538.
Tarr GP, Herbison P, de la Barra SL, Glue P (2011) Study design and 
patient characteristics and outcome in acute mania clinical 
trials. Bipolar Disord 13:125–132.
Tavares  DF, Myczkowski  ML, Alberto  RL, Valiengo  L, Rios  RM, 
Gordon  P, de  Sampaio-Junior  B, Klein  I, Mansur  CG, 
Marcolin  MA, Lafer  B, Moreno  RA, Gattaz  W, Daskalakis  ZJ, 
Brunoni AR (2017) Treatment of bipolar depression with deep 
TMS: results from a double-blind, randomized, parallel group, 
sham-controlled clinical trial. Neuropsychopharmacology 
42:2593–2601.
Taylor  DM, Cornelius  V, Smith  L, Young  AH (2014) Compara-
tive efficacy and acceptability of drug treatments for bi-
polar depression: a multiple-treatments meta-analysis. Acta 
Psychiatr Scand 130:452–469.
Thase  ME, Mallinger  AG, McKnight  D, Himmelhoch  JM (1992) 
Treatment of imipramine-resistant recurrent depression, 
IV: a double-blind crossover study of tranylcypromine for 






/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
Copyedited by:  
Fountoulakis et al. | 255
Tohen M, Waternaux CM, Tsuang MT (1990a) Outcome in Mania. 
A  4-year prospective follow-up of 75 patients utilizing sur-
vival analysis. Arch Gen Psychiatry 47:1106–1111.
Tohen M, Waternaux CM, Tsuang MT, Hunt AT (1990b) Four-year 
follow-up of twenty-four first-episode manic patients. J Af-
fect Disord 19:79–86.
Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese  JR, 
Bowden  CL, Sachs  GS, Kupfer  DJ, Baker  RW, Risser  RC, 
Keeter EL, Feldman PD, Tollefson GD, Breier A (2002) Efficacy 
of olanzapine in combination with valproate or lithium in 
the treatment of mania in patients partially nonresponsive 
to valproate or lithium monotherapy. Arch Gen Psychiatry 
59:62–69.
Tohen  M, Zarate  CA Jr, Hennen  J, Khalsa  HM, Strakowski  SM, 
Gebre-Medhin  P, Salvatore  P, Baldessarini  RJ (2003a) The 
McLean-Harvard First-Episode Mania Study: prediction of re-
covery and first recurrence. Am J Psychiatry 160:2099–2107.
Tohen  M, Ketter  TA, Zarate  CA, Suppes  T, Frye  M, Altshuler  L, 
Zajecka  J, Schuh  LM, Risser  RC, Brown  E, Baker  RW (2003b) 
Olanzapine versus divalproex sodium for the treatment of 
acute mania and maintenance of remission: a 47-week study. 
Am J Psychiatry 160:1263–1271.
Tohen  M, Chengappa  KN, Suppes  T, Baker  RW, Zarate  CA, 
Bowden  CL, Sachs  GS, Kupfer  DJ, Ghaemi  SN, Feldman  PD, 
Risser RC, Evans AR, Calabrese JR (2004) Relapse prevention 
in bipolar I  disorder: 18-month comparison of olanzapine 
plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 
184:337–345.
Tohen M, Bowden CL, Calabrese JR, Lin D, Forrester TD, Sachs GS, 
Koukopoulos A, Yatham L, Grunze H (2006) Influence of sub-
syndromal symptoms after remission from manic or mixed 
episodes. Br J Psychiatry 189:515–519.
Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, 
Malhi  GS, Calabrese  JR, Nolen  WA, Vieta  E, Kapczinski  F, 
Goodwin GM, Suppes T, Sachs GS, Chengappa KR, Grunze H, 
Mitchell PB, Kanba S, Berk M (2009) The International Society 
for Bipolar Disorders (ISBD) Task Force report on the nomen-
clature of course and outcome in bipolar disorders. Bipolar 
Disord 11:453–473.
Tondo L, Baldessarini RJ, Floris G, Rudas N (1997) Effectiveness of 
restarting lithium treatment after its discontinuation in bi-
polar I and bipolar II disorders. Am J Psychiatry 154:548–550.
Tondo L, Vázquez GH, Baldessarini RJ (2014) Options for pharma-
cological treatment of refractory bipolar depression. Curr 
Psychiatry Rep 16:431.
Tseng PT, Chen YW, Tu KY, Chung W, Wang HY, Wu CK, Lin PY (2016) 
Light therapy in the treatment of patients with bipolar de-
pression: a meta-analytic study. Eur Neuropsychopharmacol 
26:1037–1047.
Vaidya NA, Mahableshwarkar AR, Shahid R (2003) Continuation 
and maintenance ECT in treatment-resistant bipolar dis-
order. J Ect 19:10–16.
Van Lieshout RJ, MacQueen GM (2010) Efficacy and acceptability 
of mood stabilisers in the treatment of acute bipolar depres-
sion: systematic review. Br J Psychiatry 196:266–273.
Vanelle  JM, Loo  H, Galinowski  A, de  Carvalho  W, Bourdel  MC, 
Brochier P, Bouvet O, Brochier T, Olie  JP (1994) Maintenance 
ECT in intractable manic-depressive disorders. Convuls Ther 
10:195–205.
Vázquez GH, Tondo L, Undurraga J, Baldessarini RJ (2013) Over-
view of antidepressant treatment of bipolar depression. Int J 
Neuropsychopharmacol 16:1673–1685.
Veronese  N, Solmi  M, Luchini  C, Lu  RB, Stubbs  B, Zaninotto  L, 
Correll  CU (2016) Acetylcholinesterase inhibitors and 
memantine in bipolar disorder: a systematic review and best 
evidence synthesis of the efficacy and safety for multiple 
disease dimensions. J Affect Disord 197:268–280.
Versiani M, Cheniaux E, Landeira-Fernandez J (2011) Efficacy and 
safety of electroconvulsive therapy in the treatment of bi-
polar disorder: a systematic review. J Ect 27:153–164.
Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T, Calabrese JR, 
Gao K, Miskowiak KW, Grande I (2018) Bipolar disorders. Nat 
Rev Dis Primers 4:18008.
Vieta E, Garriga M (2016) Adjunctive antidepressants in bipolar 
depression. Lancet Psychiatry 3:1095–1096.
Vieta E, Gasto C, Colom F, Martinez A, Otero A, Vallejo  J (1998) 
Treatment of refractory rapid cycling bipolar disorder with 
risperidone. J Clin Psychopharmacol 18:172–174.
Vieta  E, Goikolea  JM (2005) Atypical antipsychotics: newer op-
tions for mania and maintenance therapy. Bipolar Disord 
7(Suppl 4):21–33.
Vieta  E, Manuel  Goikolea  J, Martínez-Arán  A, Comes  M, 
Verger K, Masramon X, Sanchez-Moreno J, Colom F (2006) A 
double-blind, randomized, placebo-controlled, prophylaxis 
study of adjunctive gabapentin for bipolar disorder. J Clin 
Psychiatry 67:473–477.
Vieta  E, Martinez-Arán  A, Goikolea  JM, Torrent  C, Colom  F, 
Benabarre  A, Reinares  M (2002a) A randomized trial com-
paring paroxetine and venlafaxine in the treatment of bipolar 
depressed patients taking mood stabilizers. J Clin Psychiatry 
63:508–512.
Vieta E, Popovic D, Rosa AR, Solé B, Grande I, Frey BN, Martinez-
Aran  A, Sanchez-Moreno  J, Balanzá-Martínez  V, Tabarés-
Seisdedos R, Kapczinski F (2013) The clinical implications of 
cognitive impairment and allostatic load in bipolar disorder. 
Eur Psychiatry 28:21–29.
Vieta E, Reinares M, Corbella B, Benabarre A, Gilaberte I, Colom F, 
Martínez-Arán  A, Gastó  C, Tohen  M (2001) Olanzapine as 
long-term adjunctive therapy in treatment-resistant bipolar 
disorder. J Clin Psychopharmacol 21:469–473.
Vieta E, T’joen C, McQuade RD, Carson WH Jr, Marcus RN, Sanchez R, 
Owen R, Nameche L (2008) Efficacy of adjunctive aripiprazole to 
either valproate or lithium in bipolar mania patients partially 
nonresponsive to valproate/lithium monotherapy: a placebo-
controlled study. Am J Psychiatry 165:1316–1325.
Vieta E, Torrent C, Garcia-Ribas G, Gilabert A, Garcia-Parés G, 
Rodriguez  A, Cadevall  J, García-Castrillón  J, Lusilla  P, 
Arrufat F (2002b) Use of topiramate in treatment-resistant 
bipolar spectrum disorders. J Clin Psychopharmacol 
22:431–435.
de  Vries  C, van  Bergen  A, Regeer  EJ, Benthem  E, Kupka  RW, 
Boks MP (2013) The effectiveness of restarted lithium treat-
ment after discontinuation: reviewing the evidence for 
discontinuation-induced refractoriness. Bipolar Disord 
15:645–649.
Vo D, Dunner DL (2003) Treatment-resistant bipolar disorder: a 
comparison of rapid cyclers and nonrapid cyclers. CNS Spectr 
8:948–952.
Wang  PW, Santosa  C, Schumacher  M, Winsberg  ME, Strong  C, 
Ketter TA (2002) Gabapentin augmentation therapy in bipolar 
depression. Bipolar Disord 4:296–301.
Wang PW, Yang YS, Chandler RA, Nowakowska C, Alarcon AM, 
Culver  J, Ketter TA (2008) Adjunctive zonisamide for weight 
loss in euthymic bipolar disorder patients: a pilot study. J 
Psychiatr Res 42:451–457.
Wooderson  SC, Fekadu  A, Markopoulou  K, Rane  LJ, Poon  L, 
Juruena  MF, Strawbridge  R, Cleare  AJ (2014) Long-term 






/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
256 | International Journal of Neuropsychopharmacology, 2020
sive inpatient multidisciplinary intervention for treatment-
resistant affective disorders. J Affect Disord 166:334–342.
Woźniak-Kwaśniewska  A, Szekely  D, Harquel  S, Bougerol  T, 
David  O (2015) Resting electroencephalographic correlates 
of the clinical response to repetitive transcranial magnetic 
stimulation: a preliminary comparison between unipolar and 
bipolar depression. J Affect Disord 183:15–21.
Wu JC, Kelsoe JR, Schachat C, Bunney BG, DeModena A, Golshan S, 
Gillin  JC, Potkin SG, Bunney WE (2009) Rapid and sustained 
antidepressant response with sleep deprivation and chrono-
therapy in bipolar disorder. Biol Psychiatry 66:298–301.
Xu AJ, Niciu MJ, Lundin NB, Luckenbaugh DA, Ionescu DF, Rich-
ards  EM, Vande  Voort  JL, Ballard  ED, Brutsche  NE, Machado-
Vieira R, Zarate CA Jr (2015) Lithium and valproate levels do not 
correlate with ketamine’s antidepressant efficacy in treatment-
resistant bipolar depression. Neural Plast 2015:858251.
Xu  Y, Hackett  M, Carter  G, Loo  C, Galvez  V, Glozier  N, Glue  P, 
Lapidus  K, McGirr  A, Somogyi  AA, Mitchell  PB, Rodgers  A 
(2016) Effects of low-dose and very low-dose ketamine among 
patients with major depression: a systematic review and 
meta-analysis. Int J Neuropsychopharmacol 19. pii: pyv124.
Yatham LN, Calabrese JR, Kusumakar V (2003a) Bipolar depres-
sion: criteria for treatment selection, definition of refractori-
ness, and treatment options. Bipolar Disord 5:85–97.
Yatham  LN, Grossman  F, Augustyns  I, Vieta  E, Ravindran  A 
(2003b) Mood stabilisers plus risperidone or placebo in the 
treatment of acute mania. International, double-blind, ran-
domised controlled trial. Br J Psychiatry 182:141–147.
Yatham  LN, Fallu  A, Binder  CE (2007a) A 6-month random-
ized open-label comparison of continuation of oral atypical 
antipsychotic therapy or switch to long acting injectable 
risperidone in patients with bipolar disorder. Acta Psychiatr 
Scand Suppl. 434:50–56.
Yatham LN, Vieta E, Young AH, Möller HJ, Paulsson B, Vågerö M 
(2007b) A double blind, randomized, placebo-controlled trial 
of quetiapine as an add-on therapy to lithium or divalproex 
for the treatment of bipolar mania. Int Clin Psychopharmacol 
22:212–220.
Yatham LN, Vieta E, Goodwin GM, Bourin M, de Bodinat C, Laredo J, 
Calabrese J; Agomelatine Study Group (2016) Agomelatine or 
placebo as adjunctive therapy to a mood stabiliser in bipolar 
I  depression: randomised double-blind placebo-controlled 
trial. Br J Psychiatry 208:78–86.
Yatham  LN, et  al. (2018) Canadian Network for Mood and 
Anxiety Treatments (CANMAT) and International Society 
for Bipolar Disorders (ISBD) 2018 guidelines for the man-
agement of patients with bipolar disorder. Bipolar Disord 
20:97–170.
Yorguner Kupeli N, Bulut NS, Carkaxhiu Bulut G, Kurt E, Kora K 
(2018) Efficacy of bright light therapy in bipolar depression. 
Psychiatry Res 260:432–438.
Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-
Siotis  I (2000) Double-blind comparison of addition of a 
second mood stabilizer versus an antidepressant to an ini-
tial mood stabilizer for treatment of patients with bipolar de-
pression. Am J Psychiatry 157:124–126.
Zarate  CA Jr, Brutsche  NE, Ibrahim  L, Franco-Chaves  J, 
Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, 
Luckenbaugh DA (2012) Replication of ketamine’s antidepres-
sant efficacy in bipolar depression: a randomized controlled 
add-on trial. Biol Psychiatry 71:939–946.
Zaretsky  A, Lancee  W, Miller  C, Harris  A, Parikh  SV (2008) 
Is cognitive-behavioural therapy more effective than 
psychoeducation in bipolar disorder? Can J Psychiatry 
53:441–448.
Zeinoddini A, Sorayani M, Hassanzadeh E, Arbabi M, Farokhnia M, 
Salimi S, Ghaleiha A, Akhondzadeh S (2015) Pioglitazone ad-
junctive therapy for depressive episode of bipolar disorder: a 
randomized, double-blind, placebo-controlled trial. Depress 
Anxiety 32:167–173.
Zhang Y, Yang H, Yang S, Liang W, Dai P, Wang C, Zhang Y (2013) 
Antidepressants for bipolar disorder: a meta-analysis of ran-
domized, double-blind, controlled trials. Neural Regen Res 
8:2962–2974.
Zhou TH, Dang WM, Ma YT, Hu CQ, Wang N, Zhang GY, Wang G, 
Shi C, Zhang H, Guo B, Zhou SZ, Feng L, Geng SX, Tong YZ, 
Tang GW, He ZK, Zhen L, Yu X (2018) Clinical efficacy, onset 
time and safety of bright light therapy in acute bipolar de-
pression as an adjunctive therapy: a randomized controlled 






/ijnp/article/23/4/230/5658435 by guest on 16 D
ecem
ber 2020
